{"gene":"CEBPB","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1990,"finding":"NF-IL6 (CEBPB) was cloned and identified as a member of the C/EBP family of bZIP transcription factors; the bacterially expressed protein binds CCAAT homology and viral enhancer core sequences and activates the human IL-6 promoter in a sequence-specific manner. The protein contains a leucine zipper domain and shares high homology with C/EBP at the C-terminal DNA-binding domain.","method":"Lambda gt11 library screening with NF-IL6 binding sequence, bacterial fusion protein DNA-binding assay, transfection reporter assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cloning, in vitro DNA binding reconstitution, reporter transactivation assay; foundational paper replicated widely","pmids":["2112087"],"is_preprint":false},{"year":1992,"finding":"NF-IL6 (CEBPB) is identical to IL-6DBP, the DNA-binding protein responsible for IL-6-mediated induction of acute-phase proteins. Post-translational modification (phosphorylation) increases NF-IL6 DNA-binding activity after IL-6 stimulation without increasing protein synthesis, demonstrating post-translational regulation.","method":"Protein identity comparison, DNA binding activity assays, IL-6 stimulation without protein synthesis increase","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple experimental observations in one lab; identity confirmed biochemically but mechanistic details of phosphorylation site not mapped in this paper","pmids":["1380488"],"is_preprint":false},{"year":1995,"finding":"Conditional ectopic expression of C/EBPβ in NIH-3T3 fibroblasts induces PPARγ expression and converts cells into committed preadipocytes. C/EBPβ and dexamethasone synergize to activate PPARγ transcription; C/EBPβ alone or dexamethasone alone is insufficient, establishing C/EBPβ as an upstream activator of PPARγ in the adipogenic transcriptional cascade.","method":"Tetracycline-regulated conditional expression system, stable cell line, RT-PCR, reporter assays, adipogenic differentiation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — dose-dependent conditional expression system with multiple orthogonal readouts; single lab but rigorous and widely replicated","pmids":["7557387"],"is_preprint":false},{"year":1999,"finding":"The N-terminal domain of the full-length C/EBPβ isoform (but not shorter isoforms) physically interacts with the SWI/SNF chromatin remodeling complex and recruits it to activate myeloid-specific genes (mim-1) in a chromatin context. Grafting this domain onto Myb reconstitutes SWI/SNF recruitment and mim-1 transcription in the absence of C/EBPβ.","method":"Protein interaction assays, domain swapping/chimeric activator, transcription assays in chromatin context","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with domain-swap chimera confirms sufficiency; in vitro and in vivo chromatin transcription assays","pmids":["10619021"],"is_preprint":false},{"year":2002,"finding":"Crystal structures of ternary complexes containing c-Myb DBD, C/EBPβ DBD, and promoter DNA revealed that DNA-bound C/EBPβ interacts with R2 of c-Myb bound to a separate DNA fragment, with intervening DNA looping. Point mutations in v-Myb R2 that abolish this interaction explain why v-Myb cannot cooperate with C/EBPβ. GST pulldown, luciferase assays, and atomic force microscopy confirmed this long-range interaction.","method":"X-ray crystallography, GST pulldown, luciferase transactivation assay, atomic force microscopy","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus multiple orthogonal biochemical validations in a single rigorous study","pmids":["11792321"],"is_preprint":false},{"year":2004,"finding":"Oncogenic Ras signaling phosphorylates a MAPK site in C/EBPβ, inducing a conformational change that switches C/EBPβ from a repressor to an activator. Active and repressive C/EBPβ both interact with Mediator complexes via the CRSP130/Sur2 subunit, but Ras signaling or activating mutations in C/EBPβ selectively induce association with the transcriptionally active (CRSP70-containing) Mediator complex rather than the inactive (CDK8-containing) Mediator complex. Knockdown of CRSP130/Sur2 prevents Mediator binding and transactivation.","method":"Co-immunoprecipitation, RNAi knockdown, reporter assays, conformational change analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, RNAi loss-of-function, activating mutations; multiple orthogonal approaches in one study","pmids":["14759369"],"is_preprint":false},{"year":2003,"finding":"Growth hormone (GH) rapidly relocates C/EBPβ from a diffuse nuclear distribution to pericentromeric heterochromatin in a MAPK-dependent manner. This relocation requires phosphorylation of C/EBPβ on a conserved MAPK consensus site (prevented by MEK inhibitor U0126). C/EBPβ (but not C/EBPδ) binds satellite DNA containing C/EBP sites in vitro, and GH transiently increases this binding in cells.","method":"Indirect immunofluorescence, MAPK-site-specific antibody, MEK inhibitor (U0126) treatment, DNA binding assay with satellite DNA, live cell fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal imaging and biochemical methods; single lab but rigorous with pharmacological validation","pmids":["12821655"],"is_preprint":false},{"year":1997,"finding":"CREB binds to two CRE sites in the LAP/C/EBPβ gene promoter and is required for both basal promoter activity and inducibility. The protein kinase A (PKA) pathway stimulates LAP/C/EBPβ transcription through CREB phosphorylation; mutation of CREB sites reduces promoter activity. In vivo, CREB phosphorylation correlates with LAP/C/EBPβ mRNA induction during liver regeneration.","method":"Deletion analysis, gel shift/EMSA, crosslinking, supershift, competition experiments, luciferase reporter with site-directed mutants, Northern blot, runoff transcription assay, hepatectomy model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding reconstitution with recombinant CREB, promoter mutagenesis, and in vivo transcription assay; single lab, multiple orthogonal methods","pmids":["9199295"],"is_preprint":false},{"year":1994,"finding":"C/EBPβ (NF-IL6) activates the TNFα gene promoter in cotransfection assays by binding a site that C/EBPα does not bind. A dominant-negative version of C/EBPβ blocks TNFα promoter activation in myeloid cells, establishing C/EBPβ as a direct transcriptional regulator of TNFα in macrophages.","method":"Cotransfection reporter assay, dominant-negative C/EBPβ, DNA binding assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative functional validation plus DNA binding, single lab","pmids":["7929820"],"is_preprint":false},{"year":2011,"finding":"Three amino acid substitutions in an internal regulatory domain of CEBPB in the stem lineage of placental mammals reorganized phosphorylation sites—introducing one new site and removing two ancestral sites—reversing the response of CEBPB to GSK-3β-mediated phosphorylation from repression to activation. Demonstrated by resurrecting ancestral CEBPB proteins and functionally testing their responses to cAMP/PKA signaling.","method":"Ancestral protein resurrection, functional phosphorylation assays, site-directed mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — experimental resurrection of ancestral proteins with mutagenesis; rigorous single study with multiple orthogonal functional tests","pmids":["22080951"],"is_preprint":false},{"year":2010,"finding":"The C/EBPβ isoform LIP is required for nuclear translocation of CHOP during ER stress. In early ER stress, LIP undergoes proteasomal degradation in the cytoplasm; during later ER stress, LIP binds CHOP in both cytoplasmic and nuclear compartments and acts as a vehicle for CHOP nuclear import, while CHOP stabilizes LIP. LIP-expressing C/EBPβ-null MEFs showed enhanced ER stress-induced apoptosis and decreased Bcl-2.","method":"C/EBPβ-/- MEFs, LIP expression vectors, co-immunoprecipitation, subcellular fractionation, apoptosis assays, Western blot","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — null cell complementation with specific isoforms, co-IP, fractionation, functional apoptosis readout; multiple orthogonal methods","pmids":["20479126"],"is_preprint":false},{"year":2010,"finding":"C/EBPβ LAP isoform promotes tumor progression by attenuating ER stress-triggered cell death, while the LIP isoform augments ER stress-induced apoptosis. Inducible overexpression of LIP enhanced ER stress cell death, and LAP overexpression attenuated it, both in vitro and in vivo, operating through the unfolded protein response (UPR) without affecting cell cycle or angiogenesis.","method":"Inducible overexpression, orthotopic tumor implantation, ER stress markers, cell death assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo isoform-specific gain-of-function; single lab, two orthogonal settings","pmids":["20209087"],"is_preprint":false},{"year":2006,"finding":"In TNF-tolerant monocytic cells, C/EBPβ forms complexes with NF-κB p65, specifically preventing p65 phosphorylation and thereby inhibiting NF-κB-mediated transcription. In C/EBPβ-/- cells under tolerance conditions, neither transcriptional inhibition nor p65 dephosphorylation occurs. Overexpression of C/EBPβ reduces p65-mediated transactivation.","method":"C/EBPβ-/- cell knockout, co-immunoprecipitation of C/EBPβ-p65 complex, phosphorylation assays, reporter assays, C/EBPβ overexpression","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO plus rescue, reciprocal co-IP, multiple functional readouts; single lab but multiple orthogonal approaches","pmids":["16785565"],"is_preprint":false},{"year":2007,"finding":"RSK kinase phosphorylates C/EBPβ on Thr217 (Thr266 in human) in activated hepatic stellate cells (HSCs), and this phosphorylation is critical for liver fibrosis progression. Non-phosphorylatable C/EBPβ-Ala217 was found within the death receptor complex II with active caspase-8 and induced apoptosis of activated HSCs. An RSK-inhibitory cell-permeant peptide prevented fibrosis progression.","method":"Transgenic non-phosphorylatable C/EBPβ-Ala217 mice, CCl4 fibrosis model, death receptor complex immunoprecipitation, caspase-8 cell-free system, RSK-inhibitory peptide treatment","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Strong — transgenic phospho-null mutant in vivo, cell-free reconstitution of caspase-8 activation, pharmacological intervention; multiple orthogonal approaches","pmids":["18159255"],"is_preprint":false},{"year":2004,"finding":"C/EBPβ is essential for oncogenic transformation of macrophages and promotes survival by directly transcriptionally activating IGF-I. Overexpression of C/EBPβ stimulated transcription from the IGF-I promoter; IGF-I acts as an autocrine survival factor in these tumor cells, and forced expression of either C/EBPβ or IGF-I in C/EBPβ-/- bone marrow cells restored Myc/Raf-induced transformation.","method":"C/EBPβ-/- macrophages, IGF-I neutralization, IGF-I-/- cells, C/EBPβ overexpression, IGF-I promoter reporter assay, in vivo tumor implantation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — null cells with genetic rescue, reporter assay for direct target, in vivo tumorigenicity; multiple orthogonal approaches","pmids":["15060147"],"is_preprint":false},{"year":2005,"finding":"C/EBPβ is required for transcriptional activation of regeneration-associated genes (Tα1 α-tubulin and GAP-43) following axonal injury in facial motor neurons. Injury-induced upregulation of these genes was specifically inhibited in C/EBPβ-/- mice using minimal and full Tα1 promoter reporter constructs containing functional C/EBP binding sites.","method":"C/EBPβ-/- mice, transgenic reporter constructs with C/EBP binding sites, in situ hybridization, facial nerve injury model","journal":"Molecular and cellular neurosciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mice with specific promoter reporter transgenes establishing direct transcriptional role; multiple reporter constructs and endogenous gene readouts","pmids":["15936952"],"is_preprint":false},{"year":1996,"finding":"C/EBP-β/LAP directly down-regulates albumin gene transcription during liver regeneration. Increased nuclear C/EBPβ/LAP binds the D site of the albumin promoter and inhibits transcription as shown by in vitro transcription assays with recombinant C/EBPβ/LAP and liver nuclear extracts. Pre- and post-translational mechanisms contribute to rapid nuclear accumulation after hepatectomy.","method":"In vitro transcription assay, EMSA gel shift with albumin promoter D site, hepatectomy model, transfection assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro transcription reconstitution with recombinant protein, EMSA, and in vivo hepatectomy model; multiple orthogonal methods","pmids":["8703043"],"is_preprint":false},{"year":2011,"finding":"IMiD compounds (pomalidomide, lenalidomide) down-regulate C/EBPβ protein through translational control dependent on eIF4E, without altering C/EBPβ mRNA levels or protein stability. C/EBPβ protein expression is under eIF4E translational control in multiple myeloma cells, and overexpression of C/EBPβ rescues cells from IMiD-induced anti-proliferative effects. C/EBPβ in turn transcriptionally regulates IRF4.","method":"Protein stability assays, mRNA stability assays, eIF4E manipulation, C/EBPβ overexpression rescue, reporter assays, longitudinal patient bone marrow sampling","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — translational control mechanism established by multiple exclusion experiments (not mRNA, not stability); single lab","pmids":["21389327"],"is_preprint":false},{"year":2006,"finding":"CEBPB expression is repressed in BCR/ABL-transformed myeloid cells through a translational mechanism dependent on the CUG-rich intercistronic region of C/EBPβ mRNA and the RNA-binding protein CUGBP1. Reinduction of CEBPB by imatinib or constitutive expression induced differentiation and inhibited proliferation of BCR/ABL cells; a DNA binding-deficient mutant had no effect, indicating the mechanism requires DNA binding.","method":"BCR/ABL cell model, imatinib treatment, CUGBP1 dependence assays, DNA binding-deficient mutant, in vitro and in vivo differentiation assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — translational mechanism identified with mutant; single lab, multiple approaches","pmids":["16418324"],"is_preprint":false},{"year":2015,"finding":"C/EBPβ DNA-binding activity is modulated by cytosine modifications: 5hmC in the CG dinucleotide of the C/EBP|CRE hybrid 8-mer specifically inhibits C/EBPβ binding, while 5mC, 5fC, and 5caC enhance binding. This 5hmC inhibition does not occur for C/EBPα, indicating an isoform-specific effect linked to structural differences between the two proteins.","method":"EMSA with all 25 CG modification states, circular dichroism thermal denaturation","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — systematic in vitro EMSA with orthogonal CD validation; single lab, comprehensive panel","pmids":["25779641"],"is_preprint":false},{"year":2008,"finding":"Corticosteroids induce COX-2 expression in cardiomyocytes through a mechanism requiring both the glucocorticoid receptor (GR) and C/EBPβ. Corticosterone induces GR-C/EBPβ protein-protein interaction (demonstrated by co-IP), and both GR and C/EBPβ bind the COX-2 promoter (demonstrated by ChIP). siRNA against C/EBPβ prevents corticosterone-induced COX-2 promoter activation.","method":"Co-immunoprecipitation, ChIP assay, COX-2 promoter deletion/mutation, siRNA knockdown, GR antagonist mifepristone","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, ChIP, promoter mutagenesis, and siRNA knockdown; multiple orthogonal methods in one study","pmids":["18650268"],"is_preprint":false},{"year":2012,"finding":"C/EBPβ transcriptionally represses CD200R1 expression in LPS-stimulated microglial cells. C/EBPβ binds the CD200R1 promoter directly (confirmed by qChIP). Histone deacetylase 1 (HDAC1) co-immunoprecipitates with C/EBPβ and binds a C/EBPβ consensus sequence in the CD200R1 promoter in LPS-treated cells, and HDAC inhibitors reverse C/EBPβ-mediated CD200R1 repression.","method":"qChIP, co-immunoprecipitation of HDAC1 and C/EBPβ, C/EBPβ-/- primary microglia, C/EBPβ-overexpressing BV2 cells, HDAC inhibitors","journal":"Journal of neuroinflammation","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO primary cells, overexpression, direct promoter binding by ChIP, co-IP of complex; multiple orthogonal methods","pmids":["22776069"],"is_preprint":false},{"year":2018,"finding":"Glycolysis restriction in triple-negative breast cancer represses expression of the CEBPB isoform LAP (liver-enriched activating protein) via the AMPK-ULK1 and autophagy pathways; LAP in turn controls G-CSF and GM-CSF expression to support MDSC development. The AMPK-ULK1-autophagy-CEBPB-LAP pathway links tumor glycolysis to immune suppression.","method":"Glycolysis inhibition, AMPK-ULK1 pathway manipulation, isoform-specific Western blot, TNBC mouse models, MDSC flow cytometry","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection in two mouse models with isoform-specific readouts; single lab, multiple in vivo models","pmids":["29805099"],"is_preprint":false},{"year":2013,"finding":"C/EBPβ mediates both constitutive and LPS-induced transcription of murine SerpinB2 (PAI-2) in macrophages. A C/EBP element in the SerpinB2 proximal promoter is essential for LPS inducibility (shown by mutation analysis). C/EBPβ protein forms complexes with the SerpinB2 promoter upon LPS stimulation (shown by EMSA and ChIP). Both constitutive and LPS-induced SerpinB2 expression is abrogated in C/EBPβ-null MEFs and primary peritoneal macrophages.","method":"C/EBPβ-null MEFs and peritoneal macrophages, EMSA, ChIP, reporter promoter deletion/mutation analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — null cells, ChIP, EMSA, promoter mutagenesis; multiple orthogonal approaches","pmids":["23472114"],"is_preprint":false},{"year":2019,"finding":"PRMT7 interacts with and methylates C/EBPβ upon adipogenic induction and modulates accumulation of C/EBPβ at target sites in the PPARγ2 promoter. PRMT7 depletion promotes mitotic clonal expansion and adipogenesis, while PRMT7 overexpression attenuates these processes. PRMT7-/- MEFs show increased adipogenesis.","method":"Co-immunoprecipitation, methylation assay, ChIP at PPARγ2 promoter, PRMT7-/- MEFs, adipogenesis assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP showing interaction, methylation assay, ChIP for promoter occupancy, KO MEFs; single lab","pmids":["31371025"],"is_preprint":false},{"year":2000,"finding":"C/EBPβ and Elk-1 physically interact and synergistically transactivate the c-fos serum response element (SRE) in an Ras-dependent manner. The interaction requires the C-terminal domain of C/EBPβ and the N-terminal domain of Elk-1. In vivo co-immunoprecipitation demonstrated this interaction is dependent on activated Ras signaling.","method":"GST pulldown, co-immunoprecipitation (Ras-dependent), reporter assay (Gal4-SRF and SRE reporters), domain deletion mapping","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP in vivo plus GST pulldown and reporter assays; single lab, multiple orthogonal methods","pmids":["11151091"],"is_preprint":false},{"year":2002,"finding":"C/EBP-beta (NF-IL6) mediates hypoxia-induced iNOS expression in rat pulmonary microvascular smooth muscle cells. Mutation of a C/EBP motif at -910 bp of the rat iNOS promoter abolishes hypoxia-induced promoter activity. Hypoxia increases C/EBPβ DNA-binding activity measured by EMSA.","method":"EMSA, iNOS promoter C/EBP site mutation, reporter assay, hypoxia exposure model","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed promoter mutation combined with EMSA; single lab","pmids":["11834703"],"is_preprint":false},{"year":2021,"finding":"A δ-secretase-truncated APP fragment (C586-695) directly binds CEBPB, enhances its transcriptional activity and nuclear translocation, augmenting expression of APP, MAPT, δ-secretase, and inflammatory cytokines. Full-length APP does not associate with CEBPB. Blocking δ-secretase cleavage or clearing the fragment reduces CEBPB stimulation and Alzheimer's disease pathology.","method":"Co-immunoprecipitation, nuclear translocation assay, reporter assay for CEBPB transcriptional activity, viral overexpression mouse model, antibody clearance experiment","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating direct binding, functional nuclear translocation assay, in vivo mouse model; single lab","pmids":["33880508"],"is_preprint":false},{"year":2019,"finding":"DN-ATF5 associates with CEBPB and CEBPD in cells (shown by unbiased pull-down and mass spectrometry plus immunoblotting) and interferes with their transcriptional activity. CEBPB or CEBPD knockdown promotes apoptotic death of multiple cancer cell lines but not normal astrocytes. DN-ATF5 acts by blocking CEBPB/CEBPD homodimer and heterodimer formation.","method":"Pull-down coupled with mass spectrometry, immunoblotting, siRNA knockdown of CEBPB/CEBPD, reporter assays for transcriptional activity","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — unbiased proteomics pull-down confirmed by immunoblot, siRNA functional validation; single lab","pmids":["31676720"],"is_preprint":false},{"year":2015,"finding":"MDR (multidrug-resistant) cells lack C/EBP-β LIP due to constitutive ubiquitination leading to lysosomal and proteasomal degradation. Loss of LIP drives MDR by increasing P-glycoprotein (Pgp) expression and attenuating ER stress-triggered cell death through the CHOP-caspase-3 axis. LIP overexpression reversed the MDR phenotype in vitro and in vivo.","method":"Ubiquitination assays, proteasome/lysosome inhibitors, LIP overexpression in vitro and in vivo orthotopic tumor model, Pgp expression, CHOP-caspase-3 axis analysis","journal":"Journal of the National Cancer Institute","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination mechanism plus in vitro and in vivo rescue with isoform-specific overexpression; single lab","pmids":["25766403"],"is_preprint":false},{"year":2017,"finding":"C/EBPβ in myeloid cells is required for sepsis-induced generation of immunosuppressive MDSCs. Myeloid-restricted C/EBPβ-deficient mice do not generate MDSCs upon sepsis, do not develop immunosuppression, and survive sepsis at higher rates. C/EBPβ directs a switch from pro-inflammatory to repressor myeloid phenotype, but is not required for steady-state myelopoiesis.","method":"Myeloid cell-specific Cre-lox C/EBPβ deletion, cecal ligation/puncture sepsis model, MDSC flow cytometry, adoptive transfer, colony assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — myeloid-specific conditional KO with adoptive transfer and multiple functional readouts; rigorous genetic approach","pmids":["28476751"],"is_preprint":false},{"year":2022,"finding":"NRF2 directly regulates CEBPB expression in NRF2-activated lung cancer cells; CEBPB cooperates with NRF2 to co-regulate genes involved in drug metabolism and detoxification, driving drug resistance. Comprehensive genomic analysis identified NRF2-CEBPB co-regulated genes enriched for drug resistance pathways.","method":"ChIP-seq, transcriptomic analysis of NRF2-activated lung cancer cells with CEBPB KO, drug resistance functional assays","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct regulation, KO functional assays; single lab","pmids":["35137113"],"is_preprint":false},{"year":2023,"finding":"Autophagy (SQSTM1/p62-mediated) degrades CEBPB normally; autophagy deficiency leads to CEBPB accumulation, which in turn promotes transcription of SOCS1/3. Elevated SOCS1/3 inhibits JAK1-STAT6 pathway activation and M2 macrophage marker expression, demonstrating that autophagy controls macrophage M2 polarization through CEBPB degradation.","method":"Macrophage-specific Atg5 conditional KO mice, AD skin model, CEBPB ChIP for SOCS1/3 promoters, STAT6 phosphorylation assays, flow cytometry for M2 markers","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with multiple mechanistic readouts linking autophagy-CEBPB-SOCS-JAK1-STAT6; in vivo and in vitro validation","pmids":["37963021"],"is_preprint":false},{"year":2019,"finding":"PGC1α binds CEBPB to promote CPT1A transcription and fatty acid oxidation (FAO), promoting radiation resistance in nasopharyngeal carcinoma. PGC1α/CEBPB/CPT1A constitutes a signaling axis for FAO activation.","method":"Co-immunoprecipitation of PGC1α and CEBPB, ChIP/reporter assays for CPT1A transcription, FAO assay, radiation resistance functional assay","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating direct binding, transcriptional reporter; single lab","pmids":["30945396"],"is_preprint":false},{"year":2019,"finding":"PAK4 enhances CEBPB phosphorylation on Thr-235, and CEBPB binds the -1093 to -991 bp region of the CLDN4 promoter to transcriptionally upregulate CLDN4 expression, promoting breast cancer cell migration and invasion.","method":"ChIP confirming CEBPB binding to CLDN4 promoter, PAK4 phosphorylation assay, siRNA knockdown, migration/invasion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct promoter binding plus phosphorylation assay; single lab","pmids":["30808546"],"is_preprint":false},{"year":2022,"finding":"CEBPB binds the TRIM2 promoter and acts as an upstream transcription factor for TRIM2. TRIM2 promotes p53 ubiquitination and degradation, thereby reducing p53 stability. Epinephrine signaling via β2-adrenergic receptor regulates CEBPB expression, placing CEBPB as an epinephrine-responsive upstream regulator of the TRIM2/p53 axis.","method":"ChIP assay for CEBPB binding to TRIM2 promoter, co-immunoprecipitation, p53 ubiquitination assay, β2-adrenergic receptor antagonist","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and co-IP; single lab, multiple methods","pmids":["35672760"],"is_preprint":false},{"year":2004,"finding":"The C/EBPβ isoforms LAP and LIP differentially regulate cell cycle progression in regenerating liver. Adenoviral overexpression of LAP delays S-phase entry with decreased cyclin A/E, PCNA, and CDK2 activity, via decreased C/EBPα ratio and c-jun levels. LIP overexpression leads to stronger/earlier induction of cyclin A/E and more robust C/EBPα and c-jun induction, but does not alter S-phase entry timing.","method":"Adenoviral isoform overexpression, partial hepatectomy mouse model, CDK2 activity assay, Western blot for cyclins/PCNA","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific adenoviral overexpression in vivo with mechanistic cell cycle readouts; single lab","pmids":["15368440"],"is_preprint":false},{"year":2006,"finding":"FUS-DDIT3 fusion oncogene in myxoid liposarcoma upregulates IL-6 expression in a C/EBPβ-dependent manner. siRNA knockdown of CEBPB transcripts abolishes FUS-DDIT3-induced IL-6 upregulation. ChIP revealed direct interaction between the IL-6 promoter and C/EBPβ protein in these cells.","method":"siRNA knockdown of CEBPB, ChIP assay, microarray, RT-PCR","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA functional epistasis plus ChIP for direct promoter binding; single lab","pmids":["15688424"],"is_preprint":false},{"year":2022,"finding":"CEBPB binds the Pim-1 promoter and promotes Pim-1 transcription, which facilitates NLRP3 inflammasome activation and pyroptosis in glomerular podocytes in lupus nephritis. Knockdown of CEBPB suppresses NLRP3 inflammasome activation and IL-1β/IL-6 secretion; overexpression of Pim-1 reverses these effects.","method":"ChIP for CEBPB binding to Pim-1 promoter, Pim-1 overexpression rescue, shCEBPB lentivirus in MRL/lpr mice, NLRP3 inflammasome assays","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus in vivo KD and rescue with Pim-1 OE; single lab","pmids":["36248187"],"is_preprint":false},{"year":2024,"finding":"CEBPB directly binds the SERPINA1 gene promoter and promotes SERPINA1 transcription; SERPINA1 in turn activates the STAT3 signaling pathway to promote CRC proliferation and migration. This CEBPB-SERPINA1-STAT3 axis drives colorectal cancer progression.","method":"ChIP assay, luciferase reporter gene assay, STAT3 pathway analysis, functional assays in CRC cells","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase reporter for direct regulatory relationship; single lab","pmids":["38710698"],"is_preprint":false}],"current_model":"CEBPB (C/EBP-β/NF-IL6) is a bZIP transcription factor that binds CCAAT/enhancer elements as homo- or heterodimers to directly activate or repress target genes involved in inflammation (IL-6, TNFα, G-CSF, iNOS), adipogenesis (PPARγ, C/EBPα), and survival (IGF-I, Bcl-2); its activity is post-translationally regulated by phosphorylation (via MAPK/RSK/GSK-3β/PKA/CREB cascades), isoform-specific translational control (producing the activating LAP and dominant-negative LIP isoforms from a single mRNA), ubiquitin-mediated proteasomal/lysosomal degradation (particularly of LIP), and selective association with distinct Mediator complexes (active CRSP70 vs. inactive CDK8 forms) driven by Ras-induced conformational changes; the full-length isoform additionally recruits the SWI/SNF chromatin remodeling complex through its unique N-terminal domain, and forms functional complexes with NF-κB p65 (blocking p65 phosphorylation), glucocorticoid receptor, PGC1α, CHOP, Elk-1, and HDAC1 to modulate transcription of genes controlling immunity, metabolism, differentiation, and stress responses."},"narrative":{"mechanistic_narrative":"CEBPB (C/EBPβ / NF-IL6) is a bZIP transcription factor that binds CCAAT/enhancer core elements as sequence-specific homo- or heterodimers to activate or repress genes governing inflammation, myeloid differentiation, adipogenesis, liver regeneration, and stress responses [PMID:2112087, PMID:7557387]. As a direct transcriptional regulator it activates pro-inflammatory and acute-phase targets including IL-6, TNFα, iNOS, and SerpinB2/PAI-2 [PMID:2112087, PMID:7929820, PMID:23472114, PMID:11834703], drives the adipogenic cascade by inducing PPARγ in synergy with glucocorticoid signaling [PMID:7557387], and acts as a repressor of targets such as the albumin gene during liver regeneration and CD200R1 in activated microglia, where repression is mediated by recruitment of HDAC1 [PMID:8703043, PMID:22776069]. Beyond direct DNA binding, C/EBPβ functions through protein–protein partnerships: its full-length N-terminal domain recruits the SWI/SNF chromatin-remodeling complex to activate myeloid genes [PMID:10619021], it cooperates with c-Myb through long-range DNA looping demonstrated structurally [PMID:11792321], and it forms functional complexes with the glucocorticoid receptor, PGC1α, Elk-1, NF-κB p65, and CHOP to integrate hormonal, metabolic, and stress inputs [PMID:18650268, PMID:30945396, PMID:11151091, PMID:16785565, PMID:20479126]. C/EBPβ activity is heavily controlled post-transcriptionally and post-translationally: it is converted from repressor to activator by MAPK/Ras-, RSK-, GSK-3β-, and PKA/CREB-driven phosphorylation that also dictates selective association with active versus inactive Mediator complexes and subnuclear relocalization [PMID:14759369, PMID:12821655, PMID:9199295, PMID:22080951, PMID:18159255], and the LAP and LIP isoforms produced by isoform-specific translational control exert opposing effects on ER-stress-induced apoptosis, multidrug resistance, and cell-cycle progression [PMID:20479126, PMID:20209087, PMID:25766403, PMID:15368440]. Its abundance is further set by ubiquitin-, autophagy-, and translation-dependent turnover that tunes immune polarization and inflammatory output [PMID:25766403, PMID:37963021, PMID:21389327]. In myeloid cells C/EBPβ is required for emergency generation of immunosuppressive MDSCs and for the switch from a pro-inflammatory to a repressor phenotype during sepsis and tumor-associated immune suppression [PMID:28476751, PMID:29805099]. Disease-linked roles include a δ-secretase-cleaved APP fragment that binds and hyperactivates CEBPB to amplify Alzheimer's disease pathology [PMID:33880508].","teleology":[{"year":1990,"claim":"Established the molecular identity of CEBPB as a sequence-specific bZIP activator, answering what kind of protein mediates IL-6-responsive enhancer activity.","evidence":"expression cloning, bacterial fusion-protein DNA binding, and reporter transactivation of the IL-6 promoter","pmids":["2112087"],"confidence":"High","gaps":["No in vivo target spectrum defined","Regulation of its activity not yet addressed"]},{"year":1992,"claim":"Showed CEBPB activity is controlled post-translationally, answering how IL-6 acutely boosts its function without new synthesis.","evidence":"identity comparison with IL-6DBP and DNA-binding assays after IL-6 stimulation","pmids":["1380488"],"confidence":"Medium","gaps":["Specific phosphorylation site not mapped","Responsible kinase not identified"]},{"year":1994,"claim":"Defined CEBPB as a direct macrophage TNFα activator, distinguishing it functionally from C/EBPα.","evidence":"cotransfection reporter assays with a dominant-negative C/EBPβ and DNA binding","pmids":["7929820"],"confidence":"Medium","gaps":["No endogenous knockout validation","Site occupancy in vivo not shown"]},{"year":1996,"claim":"Demonstrated CEBPB can act as a direct repressor, broadening its role beyond activation during liver regeneration.","evidence":"in vitro transcription with recombinant LAP, EMSA on the albumin D site, and hepatectomy model","pmids":["8703043"],"confidence":"High","gaps":["Corepressor machinery not identified","Isoform-specific contribution to repression unresolved"]},{"year":1997,"claim":"Identified the PKA/CREB pathway as an upstream regulator of CEBPB gene expression, linking cAMP signaling to its transcription.","evidence":"promoter deletion/mutagenesis, EMSA/supershift of CRE sites, and liver regeneration model","pmids":["9199295"],"confidence":"High","gaps":["Other inducible inputs to the promoter not enumerated"]},{"year":1995,"claim":"Placed CEBPB upstream in the adipogenic cascade, answering what initiates PPARγ induction during preadipocyte commitment.","evidence":"tetracycline-regulated conditional expression in NIH-3T3 with PPARγ readouts and differentiation assays","pmids":["7557387"],"confidence":"High","gaps":["Direct vs indirect PPARγ promoter occupancy not resolved here","Glucocorticoid synergy mechanism unclear"]},{"year":1999,"claim":"Revealed that full-length CEBPB recruits a chromatin-remodeling machine, explaining isoform-specific activation in a chromatin context.","evidence":"interaction assays plus domain-swap chimera reconstituting SWI/SNF recruitment and mim-1 transcription","pmids":["10619021"],"confidence":"High","gaps":["SWI/SNF subunit contacted not defined","Generalizability beyond myeloid genes untested"]},{"year":2000,"claim":"Showed Ras-dependent partnership with Elk-1, connecting CEBPB to growth-factor-induced immediate-early transcription.","evidence":"GST pulldown, Ras-dependent co-IP, and SRE reporter assays with domain mapping","pmids":["11151091"],"confidence":"Medium","gaps":["Endogenous SRE occupancy not shown","Single-lab interaction"]},{"year":2002,"claim":"Provided structural evidence for long-range cooperativity with c-Myb, explaining combinatorial promoter activation and v-Myb's defect.","evidence":"X-ray crystallography of ternary complexes, GST pulldown, AFM, and luciferase assays","pmids":["11792321"],"confidence":"High","gaps":["In vivo relevance of DNA looping not quantified"]},{"year":2002,"claim":"Linked CEBPB to hypoxia-induced iNOS transcription in vascular smooth muscle.","evidence":"iNOS promoter C/EBP-site mutation, EMSA, and hypoxia exposure","pmids":["11834703"],"confidence":"Medium","gaps":["No loss-of-function validation","Upstream hypoxia signaling to CEBPB unmapped"]},{"year":2003,"claim":"Established phosphorylation-driven subnuclear relocation, showing MAPK signaling repositions CEBPB to heterochromatin.","evidence":"immunofluorescence, phospho-site antibody, MEK inhibition, and satellite-DNA binding after GH stimulation","pmids":["12821655"],"confidence":"High","gaps":["Functional consequence of pericentromeric targeting unclear","Heterochromatin target genes unknown"]},{"year":2004,"claim":"Defined a Ras/MAPK conformational switch that toggles CEBPB between repressive and active Mediator complexes, providing a molecular mechanism for activity control.","evidence":"co-IP, RNAi of CRSP130/Sur2, activating mutations, and reporter assays","pmids":["14759369"],"confidence":"High","gaps":["Structural basis of the conformational change not solved","Which target genes use each Mediator form not enumerated"]},{"year":2004,"claim":"Identified IGF-I as a direct survival target through which CEBPB enables oncogenic macrophage transformation.","evidence":"C/EBPβ-null cells with genetic rescue, IGF-I promoter reporter, and in vivo tumorigenicity","pmids":["15060147"],"confidence":"High","gaps":["Direct promoter occupancy by ChIP not shown"]},{"year":2004,"claim":"Showed LAP and LIP isoforms differentially set cell-cycle timing in regenerating liver, establishing isoform-specific functional divergence.","evidence":"adenoviral isoform overexpression in partial hepatectomy with cyclin/CDK2 readouts","pmids":["15368440"],"confidence":"Medium","gaps":["Direct vs indirect cyclin regulation unclear","Single-lab in vivo overexpression"]},{"year":2005,"claim":"Established a neuronal regeneration role, showing CEBPB is required for injury-induced regeneration-associated gene transcription.","evidence":"C/EBPβ-null mice with Tα1 promoter reporter transgenes and facial nerve injury","pmids":["15936952"],"confidence":"High","gaps":["Upstream injury signaling to CEBPB not defined"]},{"year":2006,"claim":"Revealed an anti-inflammatory braking function through complex formation with NF-κB p65, blocking p65 phosphorylation during TNF tolerance.","evidence":"C/EBPβ-null cells, reciprocal co-IP, phosphorylation and reporter assays","pmids":["16785565"],"confidence":"High","gaps":["Phosphatase or kinase blocked not identified","Direct vs scaffolded inhibition unresolved"]},{"year":2006,"claim":"Showed CEBPB is a differentiation-promoting target silenced translationally by BCR/ABL, linking its loss to leukemic block.","evidence":"BCR/ABL model, imatinib reinduction, CUGBP1 dependence, and DNA-binding-deficient mutant","pmids":["16418324"],"confidence":"Medium","gaps":["Direct CUGBP1-mRNA contact not mapped here","Differentiation target genes unspecified"]},{"year":2006,"claim":"Implicated CEBPB as the effector of a fusion oncogene-driven IL-6 program in liposarcoma.","evidence":"siRNA epistasis and ChIP of CEBPB at the IL-6 promoter","pmids":["15688424"],"confidence":"Medium","gaps":["Mechanism of FUS-DDIT3 activation of CEBPB unresolved"]},{"year":2007,"claim":"Defined RSK phosphorylation of CEBPB as a fibrosis-driving survival switch in hepatic stellate cells.","evidence":"phospho-null C/EBPβ-Ala217 transgenic mice, CCl4 model, caspase-8 complex IP, and RSK-inhibitory peptide","pmids":["18159255"],"confidence":"High","gaps":["How phosphorylation excludes CEBPB from death complex II mechanistically unclear"]},{"year":2008,"claim":"Demonstrated GR–CEBPB cooperation drives corticosteroid-induced COX-2, integrating glucocorticoid signaling at a shared promoter.","evidence":"co-IP, ChIP, COX-2 promoter mutagenesis, and siRNA knockdown","pmids":["18650268"],"confidence":"High","gaps":["Stoichiometry of the GR-CEBPB complex unknown"]},{"year":2010,"claim":"Showed the LIP isoform chaperones CHOP into the nucleus and amplifies ER-stress apoptosis, defining an isoform-specific pro-death function.","evidence":"C/EBPβ-null MEFs reconstituted with LIP, co-IP, fractionation, and apoptosis assays","pmids":["20479126"],"confidence":"High","gaps":["Import receptor used for LIP-CHOP transit not identified"]},{"year":2010,"claim":"Established opposing LAP/LIP roles in tumor ER-stress survival, with LAP protecting and LIP sensitizing cells.","evidence":"inducible isoform overexpression with orthotopic tumors and UPR/cell-death markers","pmids":["20209087"],"confidence":"Medium","gaps":["Direct UPR target genes per isoform not defined"]},{"year":2011,"claim":"Captured an evolutionary rewiring of CEBPB phosphoregulation, showing how its GSK-3β/PKA response was reversed in placental mammals.","evidence":"ancestral protein resurrection with site-directed mutagenesis and functional phospho assays","pmids":["22080951"],"confidence":"High","gaps":["Physiological target genes affected by the rewiring not mapped"]},{"year":2011,"claim":"Identified eIF4E-dependent translational control of CEBPB as the basis of IMiD anti-myeloma action and linked CEBPB to IRF4 regulation.","evidence":"stability/mRNA exclusion experiments, eIF4E manipulation, rescue, and patient sampling","pmids":["21389327"],"confidence":"Medium","gaps":["Direct IRF4 promoter occupancy not shown here","Single-lab translational mechanism"]},{"year":2012,"claim":"Defined an HDAC1-dependent repressive complex through which CEBPB silences CD200R1 in activated microglia.","evidence":"qChIP, co-IP of HDAC1-CEBPB, null primary microglia, and HDAC inhibitor reversal","pmids":["22776069"],"confidence":"High","gaps":["Other corepressors not excluded"]},{"year":2013,"claim":"Established CEBPB as a direct activator of both constitutive and LPS-induced SerpinB2 in macrophages.","evidence":"C/EBPβ-null MEFs/macrophages, EMSA, ChIP, and promoter mutagenesis","pmids":["23472114"],"confidence":"High","gaps":["Cooperating LPS-responsive factors not defined"]},{"year":2015,"claim":"Showed cytosine modifications tune CEBPB DNA binding, with 5hmC selectively inhibiting it in an isoform-specific manner.","evidence":"systematic EMSA across all CG modification states with CD validation","pmids":["25779641"],"confidence":"Medium","gaps":["In vivo relevance at endogenous loci not tested"]},{"year":2015,"claim":"Linked ubiquitin-driven lysosomal/proteasomal LIP degradation to multidrug resistance through Pgp and the CHOP-caspase-3 axis.","evidence":"ubiquitination assays, degradation inhibitors, and LIP rescue in vitro and in vivo","pmids":["25766403"],"confidence":"Medium","gaps":["E3 ligase responsible for LIP ubiquitination unidentified"]},{"year":2017,"claim":"Established a myeloid-intrinsic requirement for CEBPB in sepsis-driven MDSC generation and immunosuppression.","evidence":"myeloid-specific conditional knockout, sepsis model, adoptive transfer, and MDSC profiling","pmids":["28476751"],"confidence":"High","gaps":["Direct CEBPB target genes mediating the repressor switch not enumerated"]},{"year":2018,"claim":"Connected tumor metabolism to immunosuppression through an AMPK-ULK1-autophagy axis controlling the LAP isoform and downstream G-CSF/GM-CSF.","evidence":"glycolysis inhibition, pathway manipulation, isoform-specific blots, and TNBC mouse models","pmids":["29805099"],"confidence":"Medium","gaps":["Mechanism of autophagy-dependent isoform control unclear"]},{"year":2019,"claim":"Identified PRMT7 methylation of CEBPB as a brake on its adipogenic promoter occupancy.","evidence":"co-IP, methylation assay, ChIP at PPARγ2 promoter, and PRMT7-null MEFs","pmids":["31371025"],"confidence":"Medium","gaps":["Methylated residues not mapped"]},{"year":2019,"claim":"Showed DN-ATF5 sequesters CEBPB by blocking dimer formation, and that CEBPB knockdown is selectively lethal to cancer cells.","evidence":"pull-down mass spectrometry, immunoblot, siRNA, and reporter assays","pmids":["31676720"],"confidence":"Medium","gaps":["Cancer-specific dependency mechanism unresolved"]},{"year":2019,"claim":"Defined a PGC1α-CEBPB partnership driving CPT1A transcription and fatty-acid-oxidation-dependent radioresistance.","evidence":"co-IP, ChIP/reporter for CPT1A, FAO assay, and radiation-resistance readouts","pmids":["30945396"],"confidence":"Medium","gaps":["Direct vs cooperative promoter binding not fully resolved"]},{"year":2019,"claim":"Linked PAK4 phosphorylation of CEBPB Thr-235 to CLDN4 activation and breast cancer invasion.","evidence":"ChIP at the CLDN4 promoter, phosphorylation assay, siRNA, and migration/invasion assays","pmids":["30808546"],"confidence":"Medium","gaps":["Effect of phosphorylation on DNA binding vs activity unclear"]},{"year":2021,"claim":"Revealed a δ-secretase-truncated APP fragment as a direct CEBPB activator amplifying Alzheimer's pathology.","evidence":"co-IP, nuclear translocation and reporter assays, viral mouse model, and antibody clearance","pmids":["33880508"],"confidence":"Medium","gaps":["Binding interface on CEBPB not mapped","Single-lab in vivo model"]},{"year":2022,"claim":"Identified NRF2 as a direct regulator of CEBPB and a co-regulatory partner driving detoxification-linked drug resistance.","evidence":"ChIP-seq, transcriptomics with CEBPB knockout, and drug-resistance assays","pmids":["35137113"],"confidence":"Medium","gaps":["Functional separability of NRF2 vs CEBPB contributions limited"]},{"year":2022,"claim":"Placed CEBPB upstream of the TRIM2/p53 axis as an epinephrine-responsive regulator destabilizing p53.","evidence":"ChIP at TRIM2 promoter, co-IP, p53 ubiquitination assay, and β2-adrenergic antagonist","pmids":["35672760"],"confidence":"Medium","gaps":["Direct vs indirect epinephrine-to-CEBPB link incomplete"]},{"year":2022,"claim":"Showed CEBPB drives Pim-1-dependent NLRP3 inflammasome activation and podocyte pyroptosis in lupus nephritis.","evidence":"ChIP at Pim-1 promoter, in vivo shCEBPB, and Pim-1 overexpression rescue in MRL/lpr mice","pmids":["36248187"],"confidence":"Medium","gaps":["Upstream signal activating CEBPB in podocytes unclear"]},{"year":2023,"claim":"Established that autophagy controls macrophage M2 polarization by degrading CEBPB, which otherwise drives SOCS1/3 to suppress JAK1-STAT6.","evidence":"macrophage-specific Atg5 conditional KO, CEBPB ChIP at SOCS1/3, and STAT6 phosphorylation readouts","pmids":["37963021"],"confidence":"High","gaps":["p62 recognition motif on CEBPB not defined"]},{"year":2024,"claim":"Defined a CEBPB-SERPINA1-STAT3 axis promoting colorectal cancer progression.","evidence":"ChIP, luciferase reporter, and CRC functional assays","pmids":["38710698"],"confidence":"Medium","gaps":["Direct vs indirect STAT3 activation unresolved"]},{"year":null,"claim":"How the many context-specific phosphorylation, methylation, and degradation inputs are integrated to select between CEBPB's activating and repressive output programs at the genomic level remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No genome-wide map reconciling isoform, modification state, and target choice","Structural basis of the repressor-to-activator conformational switch unsolved","E3 ligases and the full degradation network controlling each isoform incompletely defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,8,16,23,39]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,16,19,23,26]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,10,12,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,6,10,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,16,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,12,21,23,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,15,24]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,10,26]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,13,29,38]}],"complexes":[],"partners":["MYB","NFKB1/RELA","CHOP/DDIT3","ELK1","NR3C1","PPARGC1A","HDAC1","ATF5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17676","full_name":"CCAAT/enhancer-binding protein beta","aliases":["Liver activator protein","LAP","Liver-enriched inhibitory protein","LIP","Nuclear factor NF-IL6","Transcription factor 5","TCF-5"],"length_aa":345,"mass_kda":36.1,"function":"Important transcription factor regulating the expression of genes involved in immune and inflammatory responses (PubMed:12048245, PubMed:1741402, PubMed:18647749, PubMed:9374525). Also plays a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant roles with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Also plays a role in intracellular bacteria killing (By similarity). During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation (PubMed:20829347). Essential for female reproduction because of a critical role in ovarian follicle development (By similarity). Restricts osteoclastogenesis: together with NFE2L1; represses expression of DSPP during odontoblast differentiation (By similarity) Essential for gene expression induction in activated macrophages. Plays a major role in immune responses such as CD4(+) T-cell response, granuloma formation and endotoxin shock. Not essential for intracellular bacteria killing Acts as a dominant negative through heterodimerization with isoform 2 (PubMed:11741938). Promotes osteoblast differentiation and osteoclastogenesis (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P17676/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEBPB","classification":"Not Classified","n_dependent_lines":97,"n_total_lines":1208,"dependency_fraction":0.0802980132450331},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEBPB","total_profiled":1310},"omim":[{"mim_id":"620787","title":"T-CELL ACTIVATION INHIBITOR, MITOCHONDRIAL; TCAIM","url":"https://www.omim.org/entry/620787"},{"mim_id":"620521","title":"KELCH DOMAIN-CONTAINING PROTEIN 7B; KLHDC7B","url":"https://www.omim.org/entry/620521"},{"mim_id":"619246","title":"SPEXIN HORMONE; SPX","url":"https://www.omim.org/entry/619246"},{"mim_id":"615559","title":"AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE III; ALPS3","url":"https://www.omim.org/entry/615559"},{"mim_id":"614821","title":"PTCSC3 GENE; PTCSC3","url":"https://www.omim.org/entry/614821"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CEBPB"},"hgnc":{"alias_symbol":["LAP","CRP2","NFIL6","IL6DBP","C/EBP-beta"],"prev_symbol":["TCF5"]},"alphafold":{"accession":"P17676","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17676","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17676-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17676-F1-predicted_aligned_error_v6.png","plddt_mean":59.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEBPB","jax_strain_url":"https://www.jax.org/strain/search?query=CEBPB"},"sequence":{"accession":"P17676","fasta_url":"https://rest.uniprot.org/uniprotkb/P17676.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17676/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17676"}},"corpus_meta":[{"pmid":"2112087","id":"PMC_2112087","title":"A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2112087","citation_count":1463,"is_preprint":false},{"pmid":"1380488","id":"PMC_1380488","title":"IL-6 and NF-IL6 in acute-phase response and viral infection.","date":"1992","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/1380488","citation_count":472,"is_preprint":false},{"pmid":"7557387","id":"PMC_7557387","title":"Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimulates adipogenesis.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7557387","citation_count":457,"is_preprint":false},{"pmid":"7744000","id":"PMC_7744000","title":"Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7744000","citation_count":380,"is_preprint":false},{"pmid":"29805099","id":"PMC_29805099","title":"Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.","date":"2018","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29805099","citation_count":376,"is_preprint":false},{"pmid":"25451943","id":"PMC_25451943","title":"Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) β.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25451943","citation_count":294,"is_preprint":false},{"pmid":"10619021","id":"PMC_10619021","title":"A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10619021","citation_count":276,"is_preprint":false},{"pmid":"9199295","id":"PMC_9199295","title":"CREB controls LAP/C/EBP beta transcription.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9199295","citation_count":175,"is_preprint":false},{"pmid":"7929820","id":"PMC_7929820","title":"C/EBP beta regulation of the tumor necrosis factor alpha gene.","date":"1994","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/7929820","citation_count":161,"is_preprint":false},{"pmid":"14759369","id":"PMC_14759369","title":"Ras induces mediator complex exchange on C/EBP beta.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/14759369","citation_count":147,"is_preprint":false},{"pmid":"11792321","id":"PMC_11792321","title":"Mechanism of c-Myb-C/EBP beta cooperation from separated sites on a promoter.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11792321","citation_count":133,"is_preprint":false},{"pmid":"17111047","id":"PMC_17111047","title":"Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17111047","citation_count":132,"is_preprint":false},{"pmid":"9506442","id":"PMC_9506442","title":"Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9506442","citation_count":123,"is_preprint":false},{"pmid":"20479126","id":"PMC_20479126","title":"Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20479126","citation_count":94,"is_preprint":false},{"pmid":"30945396","id":"PMC_30945396","title":"PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30945396","citation_count":93,"is_preprint":false},{"pmid":"27171500","id":"PMC_27171500","title":"The circadian clock regulates autophagy directly through the nuclear hormone receptor Nr1d1/Rev-erbα and indirectly via Cebpb/(C/ebpβ) in zebrafish.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27171500","citation_count":88,"is_preprint":false},{"pmid":"21389327","id":"PMC_21389327","title":"IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21389327","citation_count":83,"is_preprint":false},{"pmid":"22080951","id":"PMC_22080951","title":"Regulatory evolution through divergence of a phosphoswitch in the transcription factor CEBPB.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22080951","citation_count":82,"is_preprint":false},{"pmid":"15936952","id":"PMC_15936952","title":"A transcriptional role for C/EBP beta in the neuronal response to axonal injury.","date":"2005","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/15936952","citation_count":79,"is_preprint":false},{"pmid":"8703043","id":"PMC_8703043","title":"C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8703043","citation_count":75,"is_preprint":false},{"pmid":"16418324","id":"PMC_16418324","title":"Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16418324","citation_count":74,"is_preprint":false},{"pmid":"16205634","id":"PMC_16205634","title":"Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16205634","citation_count":71,"is_preprint":false},{"pmid":"22495929","id":"PMC_22495929","title":"Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22495929","citation_count":67,"is_preprint":false},{"pmid":"18163952","id":"PMC_18163952","title":"The interferon signaling network and transcription factor C/EBP-beta.","date":"2007","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18163952","citation_count":66,"is_preprint":false},{"pmid":"25867276","id":"PMC_25867276","title":"C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25867276","citation_count":61,"is_preprint":false},{"pmid":"15368440","id":"PMC_15368440","title":"C/EBP beta isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15368440","citation_count":59,"is_preprint":false},{"pmid":"31338984","id":"PMC_31338984","title":"Quercetin-Induced miR-369-3p Suppresses Chronic Inflammatory Response Targeting C/EBP-β.","date":"2019","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/31338984","citation_count":58,"is_preprint":false},{"pmid":"35672760","id":"PMC_35672760","title":"Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35672760","citation_count":56,"is_preprint":false},{"pmid":"16785565","id":"PMC_16785565","title":"C/EBP beta blocks p65 phosphorylation and thereby NF-kappa B-mediated transcription in TNF-tolerant cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16785565","citation_count":54,"is_preprint":false},{"pmid":"29216750","id":"PMC_29216750","title":"PDE/cAMP/Epac/C/EBP-β Signaling Cascade Regulates Mitochondria Biogenesis of Tubular Epithelial Cells in Renal Fibrosis.","date":"2018","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29216750","citation_count":53,"is_preprint":false},{"pmid":"20209087","id":"PMC_20209087","title":"C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20209087","citation_count":52,"is_preprint":false},{"pmid":"12821655","id":"PMC_12821655","title":"Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12821655","citation_count":52,"is_preprint":false},{"pmid":"12115737","id":"PMC_12115737","title":"Transcription factors C/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes.","date":"2002","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12115737","citation_count":51,"is_preprint":false},{"pmid":"11916518","id":"PMC_11916518","title":"C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.","date":"2002","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/11916518","citation_count":50,"is_preprint":false},{"pmid":"30335837","id":"PMC_30335837","title":"Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30335837","citation_count":49,"is_preprint":false},{"pmid":"1427819","id":"PMC_1427819","title":"The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1427819","citation_count":49,"is_preprint":false},{"pmid":"26118414","id":"PMC_26118414","title":"Endogenous prostaglandin E2 potentiates anti-inflammatory phenotype of macrophage through the CREB-C/EBP-β cascade.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26118414","citation_count":48,"is_preprint":false},{"pmid":"15060147","id":"PMC_15060147","title":"Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15060147","citation_count":48,"is_preprint":false},{"pmid":"21689417","id":"PMC_21689417","title":"Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.","date":"2011","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/21689417","citation_count":48,"is_preprint":false},{"pmid":"1385054","id":"PMC_1385054","title":"Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6.","date":"1992","source":"Ciba Foundation symposium","url":"https://pubmed.ncbi.nlm.nih.gov/1385054","citation_count":47,"is_preprint":false},{"pmid":"15688424","id":"PMC_15688424","title":"Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15688424","citation_count":45,"is_preprint":false},{"pmid":"25766403","id":"PMC_25766403","title":"The role of C/EBP-β LIP in multidrug resistance.","date":"2015","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/25766403","citation_count":42,"is_preprint":false},{"pmid":"28476751","id":"PMC_28476751","title":"Frontline Science: Myeloid cell-specific deletion of Cebpb decreases sepsis-induced immunosuppression in mice.","date":"2017","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/28476751","citation_count":42,"is_preprint":false},{"pmid":"22776069","id":"PMC_22776069","title":"Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells.","date":"2012","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22776069","citation_count":42,"is_preprint":false},{"pmid":"27011164","id":"PMC_27011164","title":"C/EBP β Mediates Endoplasmic Reticulum Stress Regulated Inflammatory Response and Extracellular Matrix Degradation in LPS-Stimulated Human Periodontal Ligament Cells.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27011164","citation_count":41,"is_preprint":false},{"pmid":"34837101","id":"PMC_34837101","title":"Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/34837101","citation_count":40,"is_preprint":false},{"pmid":"18159255","id":"PMC_18159255","title":"A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18159255","citation_count":40,"is_preprint":false},{"pmid":"30808546","id":"PMC_30808546","title":"A novel PAK4-CEBPB-CLDN4 axis involving in breast cancer cell migration and invasion.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30808546","citation_count":39,"is_preprint":false},{"pmid":"37963021","id":"PMC_37963021","title":"Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37963021","citation_count":38,"is_preprint":false},{"pmid":"31676720","id":"PMC_31676720","title":"Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31676720","citation_count":38,"is_preprint":false},{"pmid":"30482226","id":"PMC_30482226","title":"Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30482226","citation_count":37,"is_preprint":false},{"pmid":"34101546","id":"PMC_34101546","title":"Garcinia cambogia attenuates adipogenesis by affecting CEBPB and SQSTM1/p62-mediated selective autophagic degradation of KLF3 through RPS6KA1 and STAT3 suppression.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34101546","citation_count":36,"is_preprint":false},{"pmid":"19297554","id":"PMC_19297554","title":"C/EBP-beta modulates transcription of tubulointerstitial nephritis antigen in obstructive uropathy.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19297554","citation_count":36,"is_preprint":false},{"pmid":"23881867","id":"PMC_23881867","title":"Reciprocal modulation of C/EBP-α and C/EBP-β by IL-13 in activated microglia prevents neuronal death.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23881867","citation_count":36,"is_preprint":false},{"pmid":"33880508","id":"PMC_33880508","title":"A delta-secretase-truncated APP fragment activates CEBPB, mediating Alzheimer's disease pathologies.","date":"2021","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33880508","citation_count":35,"is_preprint":false},{"pmid":"25779641","id":"PMC_25779641","title":"C/EBPβ (CEBPB) protein binding to the C/EBP|CRE DNA 8-mer TTGC|GTCA is inhibited by 5hmC and enhanced by 5mC, 5fC, and 5caC in the CG dinucleotide.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25779641","citation_count":35,"is_preprint":false},{"pmid":"10370372","id":"PMC_10370372","title":"C/EBP beta in rheumatoid arthritis: correlation with inflammation, not disease specificity.","date":"1999","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/10370372","citation_count":33,"is_preprint":false},{"pmid":"26372225","id":"PMC_26372225","title":"XBP1-Independent UPR Pathways Suppress C/EBP-β Mediated Chondrocyte Differentiation in ER-Stress Related Skeletal Disease.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26372225","citation_count":33,"is_preprint":false},{"pmid":"38710698","id":"PMC_38710698","title":"CEBPB-mediated upregulation of SERPINA1 promotes colorectal cancer progression by enhancing STAT3 signaling.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38710698","citation_count":33,"is_preprint":false},{"pmid":"29748013","id":"PMC_29748013","title":"Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.","date":"2018","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/29748013","citation_count":32,"is_preprint":false},{"pmid":"12890646","id":"PMC_12890646","title":"Regulation of elastin gene transcription by interleukin-1 beta-induced C/EBP beta isoforms.","date":"2003","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12890646","citation_count":32,"is_preprint":false},{"pmid":"26670206","id":"PMC_26670206","title":"CD200 increases alternatively activated macrophages through cAMP-response element binding protein - C/EBP-beta signaling.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26670206","citation_count":32,"is_preprint":false},{"pmid":"34065488","id":"PMC_34065488","title":"Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34065488","citation_count":31,"is_preprint":false},{"pmid":"35137113","id":"PMC_35137113","title":"CEBPB is required for NRF2-mediated drug resistance in NRF2-activated non-small cell lung cancer cells.","date":"2022","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35137113","citation_count":28,"is_preprint":false},{"pmid":"8774705","id":"PMC_8774705","title":"Nuclear factor kappa B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta (NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line.","date":"1996","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8774705","citation_count":27,"is_preprint":false},{"pmid":"11834703","id":"PMC_11834703","title":"C/EBP-beta mediates iNOS induction by hypoxia in rat pulmonary microvascular smooth muscle cells.","date":"2002","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11834703","citation_count":27,"is_preprint":false},{"pmid":"18439838","id":"PMC_18439838","title":"Loss of c/EBP-beta activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons.","date":"2008","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18439838","citation_count":27,"is_preprint":false},{"pmid":"21308746","id":"PMC_21308746","title":"Role of C/EBP-β, p38 MAPK, and MKK6 in IL-1β-mediated C3 gene regulation in astrocytes.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21308746","citation_count":27,"is_preprint":false},{"pmid":"1889804","id":"PMC_1889804","title":"The Interleukin-6-dependent DNA-binding protein gene (transcription factor 5: TCF5) maps to human chromosome 20 and rat chromosome 3, the IL6 receptor locus (IL6R) to human chromosome 1 and rat chromosome 2, and the rat IL6 gene to rat chromosome 4.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1889804","citation_count":26,"is_preprint":false},{"pmid":"18512730","id":"PMC_18512730","title":"Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cells.","date":"2008","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/18512730","citation_count":26,"is_preprint":false},{"pmid":"21600648","id":"PMC_21600648","title":"C/EBP-α and C/EBP-β-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine).","date":"2011","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/21600648","citation_count":26,"is_preprint":false},{"pmid":"18650268","id":"PMC_18650268","title":"Corticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-beta.","date":"2008","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18650268","citation_count":26,"is_preprint":false},{"pmid":"11779194","id":"PMC_11779194","title":"Proteasome inhibitors activate the transcription factors C/EBP-beta and delta in human intestinal epithelial cells.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11779194","citation_count":26,"is_preprint":false},{"pmid":"36728807","id":"PMC_36728807","title":"CEBPB regulates the migration, invasion and EMT of breast cancer cells by inhibiting THBS2 expression and O-fucosylation.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36728807","citation_count":25,"is_preprint":false},{"pmid":"33892791","id":"PMC_33892791","title":"DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33892791","citation_count":25,"is_preprint":false},{"pmid":"32297103","id":"PMC_32297103","title":"microRNA-381-3p Confers Protection Against Ischemic Stroke Through Promoting Angiogenesis and Inhibiting Inflammation by Suppressing Cebpb and Map3k8.","date":"2020","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32297103","citation_count":25,"is_preprint":false},{"pmid":"19222842","id":"PMC_19222842","title":"Cyclic regulation of transcription factor C/EBP beta in human endometrium.","date":"2009","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/19222842","citation_count":25,"is_preprint":false},{"pmid":"36831248","id":"PMC_36831248","title":"Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36831248","citation_count":23,"is_preprint":false},{"pmid":"35674458","id":"PMC_35674458","title":"PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway.","date":"2022","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35674458","citation_count":23,"is_preprint":false},{"pmid":"16784777","id":"PMC_16784777","title":"Differential roles of C/EBP beta regulatory domains in specifying MCP-1 and IL-6 transcription.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16784777","citation_count":23,"is_preprint":false},{"pmid":"38994023","id":"PMC_38994023","title":"The CEBPB+ glioblastoma subcluster specifically drives the formation of M2 tumor-associated macrophages to promote malignancy growth.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38994023","citation_count":22,"is_preprint":false},{"pmid":"34792688","id":"PMC_34792688","title":"Short-Chain Fatty Acid Decreases the Expression of CEBPB to Inhibit miR-145-Mediated DUSP6 and Thus Further Suppresses Intestinal Inflammation.","date":"2021","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34792688","citation_count":22,"is_preprint":false},{"pmid":"26168729","id":"PMC_26168729","title":"Accelerated apoptosis of peripheral blood monocytes in Cebpb-deficient mice.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26168729","citation_count":22,"is_preprint":false},{"pmid":"40037690","id":"PMC_40037690","title":"CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma.","date":"2025","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40037690","citation_count":21,"is_preprint":false},{"pmid":"30775317","id":"PMC_30775317","title":"Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30775317","citation_count":21,"is_preprint":false},{"pmid":"31314588","id":"PMC_31314588","title":"Downregulated Long Noncoding RNA GAS5 Fails to Function as Decoy of CEBPB, Resulting in Increased GDF15 Expression and Rapid Ovarian Cancer Cell Proliferation.","date":"2019","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/31314588","citation_count":21,"is_preprint":false},{"pmid":"36248187","id":"PMC_36248187","title":"Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling.","date":"2022","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36248187","citation_count":20,"is_preprint":false},{"pmid":"35365168","id":"PMC_35365168","title":"CircZDBF2 up-regulates RNF145 by ceRNA model and recruits CEBPB to accelerate oral squamous cell carcinoma progression via NFκB signaling pathway.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35365168","citation_count":20,"is_preprint":false},{"pmid":"38008054","id":"PMC_38008054","title":"Melatonin alleviates the toxic effect of di(2-ethylhexyl) phthalate on oocyte quality resulting from CEBPB suppression during primordial follicle formation.","date":"2023","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38008054","citation_count":19,"is_preprint":false},{"pmid":"36129029","id":"PMC_36129029","title":"CEBPB regulates the bile acid receptor FXR to accelerate colon cancer progression by modulating aerobic glycolysis.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/36129029","citation_count":18,"is_preprint":false},{"pmid":"23472114","id":"PMC_23472114","title":"The transcription factor C/EBP-β mediates constitutive and LPS-inducible transcription of murine SerpinB2.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23472114","citation_count":18,"is_preprint":false},{"pmid":"38278779","id":"PMC_38278779","title":"Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/38278779","citation_count":17,"is_preprint":false},{"pmid":"29581460","id":"PMC_29581460","title":"Loss of Stemness, EMT, and Supernumerary Tooth Formation in Cebpb-/-Runx2+/- Murine Incisors.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29581460","citation_count":17,"is_preprint":false},{"pmid":"30010083","id":"PMC_30010083","title":"A two phase regulation of bone regeneration: IL-17F mediates osteoblastogenesis via C/EBP-β in vitro.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/30010083","citation_count":17,"is_preprint":false},{"pmid":"38017373","id":"PMC_38017373","title":"IGF2 deficiency promotes liver aging through mitochondrial dysfunction and upregulated CEBPB signaling in D-galactose-induced aging mice.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/38017373","citation_count":16,"is_preprint":false},{"pmid":"31371025","id":"PMC_31371025","title":"PRMT7 deficiency enhances adipogenesis through modulation of C/EBP-β.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31371025","citation_count":16,"is_preprint":false},{"pmid":"11151091","id":"PMC_11151091","title":"C/EBP beta and Elk-1 synergistically transactivate the c-fos serum response element.","date":"2000","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11151091","citation_count":16,"is_preprint":false},{"pmid":"37944732","id":"PMC_37944732","title":"CircDYM attenuates microglial apoptosis via CEBPB/ZC3H4 axis in LPS-induced mouse model of depression.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37944732","citation_count":16,"is_preprint":false},{"pmid":"39488922","id":"PMC_39488922","title":"Isoliquiritigenin alleviates neuropathic pain by reducing microglia inflammation through inhibition of the ERK signaling pathway and decreasing CEBPB transcription expression.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39488922","citation_count":15,"is_preprint":false},{"pmid":"35910380","id":"PMC_35910380","title":"Nintedanib Alleviates Experimental Colitis by Inhibiting CEBPB/PCK1 and CEBPB/EFNA1 Pathways.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35910380","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52704,"output_tokens":10639,"usd":0.158849,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21511,"output_tokens":8759,"usd":0.163265,"stage2_stop_reason":"end_turn"},"total_usd":0.322114,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"NF-IL6 (CEBPB) was cloned and identified as a member of the C/EBP family of bZIP transcription factors; the bacterially expressed protein binds CCAAT homology and viral enhancer core sequences and activates the human IL-6 promoter in a sequence-specific manner. The protein contains a leucine zipper domain and shares high homology with C/EBP at the C-terminal DNA-binding domain.\",\n      \"method\": \"Lambda gt11 library screening with NF-IL6 binding sequence, bacterial fusion protein DNA-binding assay, transfection reporter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cloning, in vitro DNA binding reconstitution, reporter transactivation assay; foundational paper replicated widely\",\n      \"pmids\": [\"2112087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"NF-IL6 (CEBPB) is identical to IL-6DBP, the DNA-binding protein responsible for IL-6-mediated induction of acute-phase proteins. Post-translational modification (phosphorylation) increases NF-IL6 DNA-binding activity after IL-6 stimulation without increasing protein synthesis, demonstrating post-translational regulation.\",\n      \"method\": \"Protein identity comparison, DNA binding activity assays, IL-6 stimulation without protein synthesis increase\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple experimental observations in one lab; identity confirmed biochemically but mechanistic details of phosphorylation site not mapped in this paper\",\n      \"pmids\": [\"1380488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Conditional ectopic expression of C/EBPβ in NIH-3T3 fibroblasts induces PPARγ expression and converts cells into committed preadipocytes. C/EBPβ and dexamethasone synergize to activate PPARγ transcription; C/EBPβ alone or dexamethasone alone is insufficient, establishing C/EBPβ as an upstream activator of PPARγ in the adipogenic transcriptional cascade.\",\n      \"method\": \"Tetracycline-regulated conditional expression system, stable cell line, RT-PCR, reporter assays, adipogenic differentiation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dose-dependent conditional expression system with multiple orthogonal readouts; single lab but rigorous and widely replicated\",\n      \"pmids\": [\"7557387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The N-terminal domain of the full-length C/EBPβ isoform (but not shorter isoforms) physically interacts with the SWI/SNF chromatin remodeling complex and recruits it to activate myeloid-specific genes (mim-1) in a chromatin context. Grafting this domain onto Myb reconstitutes SWI/SNF recruitment and mim-1 transcription in the absence of C/EBPβ.\",\n      \"method\": \"Protein interaction assays, domain swapping/chimeric activator, transcription assays in chromatin context\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with domain-swap chimera confirms sufficiency; in vitro and in vivo chromatin transcription assays\",\n      \"pmids\": [\"10619021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structures of ternary complexes containing c-Myb DBD, C/EBPβ DBD, and promoter DNA revealed that DNA-bound C/EBPβ interacts with R2 of c-Myb bound to a separate DNA fragment, with intervening DNA looping. Point mutations in v-Myb R2 that abolish this interaction explain why v-Myb cannot cooperate with C/EBPβ. GST pulldown, luciferase assays, and atomic force microscopy confirmed this long-range interaction.\",\n      \"method\": \"X-ray crystallography, GST pulldown, luciferase transactivation assay, atomic force microscopy\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus multiple orthogonal biochemical validations in a single rigorous study\",\n      \"pmids\": [\"11792321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Oncogenic Ras signaling phosphorylates a MAPK site in C/EBPβ, inducing a conformational change that switches C/EBPβ from a repressor to an activator. Active and repressive C/EBPβ both interact with Mediator complexes via the CRSP130/Sur2 subunit, but Ras signaling or activating mutations in C/EBPβ selectively induce association with the transcriptionally active (CRSP70-containing) Mediator complex rather than the inactive (CDK8-containing) Mediator complex. Knockdown of CRSP130/Sur2 prevents Mediator binding and transactivation.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, reporter assays, conformational change analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, RNAi loss-of-function, activating mutations; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"14759369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Growth hormone (GH) rapidly relocates C/EBPβ from a diffuse nuclear distribution to pericentromeric heterochromatin in a MAPK-dependent manner. This relocation requires phosphorylation of C/EBPβ on a conserved MAPK consensus site (prevented by MEK inhibitor U0126). C/EBPβ (but not C/EBPδ) binds satellite DNA containing C/EBP sites in vitro, and GH transiently increases this binding in cells.\",\n      \"method\": \"Indirect immunofluorescence, MAPK-site-specific antibody, MEK inhibitor (U0126) treatment, DNA binding assay with satellite DNA, live cell fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal imaging and biochemical methods; single lab but rigorous with pharmacological validation\",\n      \"pmids\": [\"12821655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CREB binds to two CRE sites in the LAP/C/EBPβ gene promoter and is required for both basal promoter activity and inducibility. The protein kinase A (PKA) pathway stimulates LAP/C/EBPβ transcription through CREB phosphorylation; mutation of CREB sites reduces promoter activity. In vivo, CREB phosphorylation correlates with LAP/C/EBPβ mRNA induction during liver regeneration.\",\n      \"method\": \"Deletion analysis, gel shift/EMSA, crosslinking, supershift, competition experiments, luciferase reporter with site-directed mutants, Northern blot, runoff transcription assay, hepatectomy model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding reconstitution with recombinant CREB, promoter mutagenesis, and in vivo transcription assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"9199295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C/EBPβ (NF-IL6) activates the TNFα gene promoter in cotransfection assays by binding a site that C/EBPα does not bind. A dominant-negative version of C/EBPβ blocks TNFα promoter activation in myeloid cells, establishing C/EBPβ as a direct transcriptional regulator of TNFα in macrophages.\",\n      \"method\": \"Cotransfection reporter assay, dominant-negative C/EBPβ, DNA binding assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative functional validation plus DNA binding, single lab\",\n      \"pmids\": [\"7929820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Three amino acid substitutions in an internal regulatory domain of CEBPB in the stem lineage of placental mammals reorganized phosphorylation sites—introducing one new site and removing two ancestral sites—reversing the response of CEBPB to GSK-3β-mediated phosphorylation from repression to activation. Demonstrated by resurrecting ancestral CEBPB proteins and functionally testing their responses to cAMP/PKA signaling.\",\n      \"method\": \"Ancestral protein resurrection, functional phosphorylation assays, site-directed mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — experimental resurrection of ancestral proteins with mutagenesis; rigorous single study with multiple orthogonal functional tests\",\n      \"pmids\": [\"22080951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The C/EBPβ isoform LIP is required for nuclear translocation of CHOP during ER stress. In early ER stress, LIP undergoes proteasomal degradation in the cytoplasm; during later ER stress, LIP binds CHOP in both cytoplasmic and nuclear compartments and acts as a vehicle for CHOP nuclear import, while CHOP stabilizes LIP. LIP-expressing C/EBPβ-null MEFs showed enhanced ER stress-induced apoptosis and decreased Bcl-2.\",\n      \"method\": \"C/EBPβ-/- MEFs, LIP expression vectors, co-immunoprecipitation, subcellular fractionation, apoptosis assays, Western blot\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — null cell complementation with specific isoforms, co-IP, fractionation, functional apoptosis readout; multiple orthogonal methods\",\n      \"pmids\": [\"20479126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"C/EBPβ LAP isoform promotes tumor progression by attenuating ER stress-triggered cell death, while the LIP isoform augments ER stress-induced apoptosis. Inducible overexpression of LIP enhanced ER stress cell death, and LAP overexpression attenuated it, both in vitro and in vivo, operating through the unfolded protein response (UPR) without affecting cell cycle or angiogenesis.\",\n      \"method\": \"Inducible overexpression, orthotopic tumor implantation, ER stress markers, cell death assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo isoform-specific gain-of-function; single lab, two orthogonal settings\",\n      \"pmids\": [\"20209087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In TNF-tolerant monocytic cells, C/EBPβ forms complexes with NF-κB p65, specifically preventing p65 phosphorylation and thereby inhibiting NF-κB-mediated transcription. In C/EBPβ-/- cells under tolerance conditions, neither transcriptional inhibition nor p65 dephosphorylation occurs. Overexpression of C/EBPβ reduces p65-mediated transactivation.\",\n      \"method\": \"C/EBPβ-/- cell knockout, co-immunoprecipitation of C/EBPβ-p65 complex, phosphorylation assays, reporter assays, C/EBPβ overexpression\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO plus rescue, reciprocal co-IP, multiple functional readouts; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"16785565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RSK kinase phosphorylates C/EBPβ on Thr217 (Thr266 in human) in activated hepatic stellate cells (HSCs), and this phosphorylation is critical for liver fibrosis progression. Non-phosphorylatable C/EBPβ-Ala217 was found within the death receptor complex II with active caspase-8 and induced apoptosis of activated HSCs. An RSK-inhibitory cell-permeant peptide prevented fibrosis progression.\",\n      \"method\": \"Transgenic non-phosphorylatable C/EBPβ-Ala217 mice, CCl4 fibrosis model, death receptor complex immunoprecipitation, caspase-8 cell-free system, RSK-inhibitory peptide treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — transgenic phospho-null mutant in vivo, cell-free reconstitution of caspase-8 activation, pharmacological intervention; multiple orthogonal approaches\",\n      \"pmids\": [\"18159255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"C/EBPβ is essential for oncogenic transformation of macrophages and promotes survival by directly transcriptionally activating IGF-I. Overexpression of C/EBPβ stimulated transcription from the IGF-I promoter; IGF-I acts as an autocrine survival factor in these tumor cells, and forced expression of either C/EBPβ or IGF-I in C/EBPβ-/- bone marrow cells restored Myc/Raf-induced transformation.\",\n      \"method\": \"C/EBPβ-/- macrophages, IGF-I neutralization, IGF-I-/- cells, C/EBPβ overexpression, IGF-I promoter reporter assay, in vivo tumor implantation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — null cells with genetic rescue, reporter assay for direct target, in vivo tumorigenicity; multiple orthogonal approaches\",\n      \"pmids\": [\"15060147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"C/EBPβ is required for transcriptional activation of regeneration-associated genes (Tα1 α-tubulin and GAP-43) following axonal injury in facial motor neurons. Injury-induced upregulation of these genes was specifically inhibited in C/EBPβ-/- mice using minimal and full Tα1 promoter reporter constructs containing functional C/EBP binding sites.\",\n      \"method\": \"C/EBPβ-/- mice, transgenic reporter constructs with C/EBP binding sites, in situ hybridization, facial nerve injury model\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mice with specific promoter reporter transgenes establishing direct transcriptional role; multiple reporter constructs and endogenous gene readouts\",\n      \"pmids\": [\"15936952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"C/EBP-β/LAP directly down-regulates albumin gene transcription during liver regeneration. Increased nuclear C/EBPβ/LAP binds the D site of the albumin promoter and inhibits transcription as shown by in vitro transcription assays with recombinant C/EBPβ/LAP and liver nuclear extracts. Pre- and post-translational mechanisms contribute to rapid nuclear accumulation after hepatectomy.\",\n      \"method\": \"In vitro transcription assay, EMSA gel shift with albumin promoter D site, hepatectomy model, transfection assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro transcription reconstitution with recombinant protein, EMSA, and in vivo hepatectomy model; multiple orthogonal methods\",\n      \"pmids\": [\"8703043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IMiD compounds (pomalidomide, lenalidomide) down-regulate C/EBPβ protein through translational control dependent on eIF4E, without altering C/EBPβ mRNA levels or protein stability. C/EBPβ protein expression is under eIF4E translational control in multiple myeloma cells, and overexpression of C/EBPβ rescues cells from IMiD-induced anti-proliferative effects. C/EBPβ in turn transcriptionally regulates IRF4.\",\n      \"method\": \"Protein stability assays, mRNA stability assays, eIF4E manipulation, C/EBPβ overexpression rescue, reporter assays, longitudinal patient bone marrow sampling\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — translational control mechanism established by multiple exclusion experiments (not mRNA, not stability); single lab\",\n      \"pmids\": [\"21389327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CEBPB expression is repressed in BCR/ABL-transformed myeloid cells through a translational mechanism dependent on the CUG-rich intercistronic region of C/EBPβ mRNA and the RNA-binding protein CUGBP1. Reinduction of CEBPB by imatinib or constitutive expression induced differentiation and inhibited proliferation of BCR/ABL cells; a DNA binding-deficient mutant had no effect, indicating the mechanism requires DNA binding.\",\n      \"method\": \"BCR/ABL cell model, imatinib treatment, CUGBP1 dependence assays, DNA binding-deficient mutant, in vitro and in vivo differentiation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — translational mechanism identified with mutant; single lab, multiple approaches\",\n      \"pmids\": [\"16418324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"C/EBPβ DNA-binding activity is modulated by cytosine modifications: 5hmC in the CG dinucleotide of the C/EBP|CRE hybrid 8-mer specifically inhibits C/EBPβ binding, while 5mC, 5fC, and 5caC enhance binding. This 5hmC inhibition does not occur for C/EBPα, indicating an isoform-specific effect linked to structural differences between the two proteins.\",\n      \"method\": \"EMSA with all 25 CG modification states, circular dichroism thermal denaturation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic in vitro EMSA with orthogonal CD validation; single lab, comprehensive panel\",\n      \"pmids\": [\"25779641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Corticosteroids induce COX-2 expression in cardiomyocytes through a mechanism requiring both the glucocorticoid receptor (GR) and C/EBPβ. Corticosterone induces GR-C/EBPβ protein-protein interaction (demonstrated by co-IP), and both GR and C/EBPβ bind the COX-2 promoter (demonstrated by ChIP). siRNA against C/EBPβ prevents corticosterone-induced COX-2 promoter activation.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, COX-2 promoter deletion/mutation, siRNA knockdown, GR antagonist mifepristone\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, ChIP, promoter mutagenesis, and siRNA knockdown; multiple orthogonal methods in one study\",\n      \"pmids\": [\"18650268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"C/EBPβ transcriptionally represses CD200R1 expression in LPS-stimulated microglial cells. C/EBPβ binds the CD200R1 promoter directly (confirmed by qChIP). Histone deacetylase 1 (HDAC1) co-immunoprecipitates with C/EBPβ and binds a C/EBPβ consensus sequence in the CD200R1 promoter in LPS-treated cells, and HDAC inhibitors reverse C/EBPβ-mediated CD200R1 repression.\",\n      \"method\": \"qChIP, co-immunoprecipitation of HDAC1 and C/EBPβ, C/EBPβ-/- primary microglia, C/EBPβ-overexpressing BV2 cells, HDAC inhibitors\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO primary cells, overexpression, direct promoter binding by ChIP, co-IP of complex; multiple orthogonal methods\",\n      \"pmids\": [\"22776069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Glycolysis restriction in triple-negative breast cancer represses expression of the CEBPB isoform LAP (liver-enriched activating protein) via the AMPK-ULK1 and autophagy pathways; LAP in turn controls G-CSF and GM-CSF expression to support MDSC development. The AMPK-ULK1-autophagy-CEBPB-LAP pathway links tumor glycolysis to immune suppression.\",\n      \"method\": \"Glycolysis inhibition, AMPK-ULK1 pathway manipulation, isoform-specific Western blot, TNBC mouse models, MDSC flow cytometry\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection in two mouse models with isoform-specific readouts; single lab, multiple in vivo models\",\n      \"pmids\": [\"29805099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"C/EBPβ mediates both constitutive and LPS-induced transcription of murine SerpinB2 (PAI-2) in macrophages. A C/EBP element in the SerpinB2 proximal promoter is essential for LPS inducibility (shown by mutation analysis). C/EBPβ protein forms complexes with the SerpinB2 promoter upon LPS stimulation (shown by EMSA and ChIP). Both constitutive and LPS-induced SerpinB2 expression is abrogated in C/EBPβ-null MEFs and primary peritoneal macrophages.\",\n      \"method\": \"C/EBPβ-null MEFs and peritoneal macrophages, EMSA, ChIP, reporter promoter deletion/mutation analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — null cells, ChIP, EMSA, promoter mutagenesis; multiple orthogonal approaches\",\n      \"pmids\": [\"23472114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRMT7 interacts with and methylates C/EBPβ upon adipogenic induction and modulates accumulation of C/EBPβ at target sites in the PPARγ2 promoter. PRMT7 depletion promotes mitotic clonal expansion and adipogenesis, while PRMT7 overexpression attenuates these processes. PRMT7-/- MEFs show increased adipogenesis.\",\n      \"method\": \"Co-immunoprecipitation, methylation assay, ChIP at PPARγ2 promoter, PRMT7-/- MEFs, adipogenesis assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP showing interaction, methylation assay, ChIP for promoter occupancy, KO MEFs; single lab\",\n      \"pmids\": [\"31371025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"C/EBPβ and Elk-1 physically interact and synergistically transactivate the c-fos serum response element (SRE) in an Ras-dependent manner. The interaction requires the C-terminal domain of C/EBPβ and the N-terminal domain of Elk-1. In vivo co-immunoprecipitation demonstrated this interaction is dependent on activated Ras signaling.\",\n      \"method\": \"GST pulldown, co-immunoprecipitation (Ras-dependent), reporter assay (Gal4-SRF and SRE reporters), domain deletion mapping\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP in vivo plus GST pulldown and reporter assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"11151091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"C/EBP-beta (NF-IL6) mediates hypoxia-induced iNOS expression in rat pulmonary microvascular smooth muscle cells. Mutation of a C/EBP motif at -910 bp of the rat iNOS promoter abolishes hypoxia-induced promoter activity. Hypoxia increases C/EBPβ DNA-binding activity measured by EMSA.\",\n      \"method\": \"EMSA, iNOS promoter C/EBP site mutation, reporter assay, hypoxia exposure model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed promoter mutation combined with EMSA; single lab\",\n      \"pmids\": [\"11834703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A δ-secretase-truncated APP fragment (C586-695) directly binds CEBPB, enhances its transcriptional activity and nuclear translocation, augmenting expression of APP, MAPT, δ-secretase, and inflammatory cytokines. Full-length APP does not associate with CEBPB. Blocking δ-secretase cleavage or clearing the fragment reduces CEBPB stimulation and Alzheimer's disease pathology.\",\n      \"method\": \"Co-immunoprecipitation, nuclear translocation assay, reporter assay for CEBPB transcriptional activity, viral overexpression mouse model, antibody clearance experiment\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating direct binding, functional nuclear translocation assay, in vivo mouse model; single lab\",\n      \"pmids\": [\"33880508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DN-ATF5 associates with CEBPB and CEBPD in cells (shown by unbiased pull-down and mass spectrometry plus immunoblotting) and interferes with their transcriptional activity. CEBPB or CEBPD knockdown promotes apoptotic death of multiple cancer cell lines but not normal astrocytes. DN-ATF5 acts by blocking CEBPB/CEBPD homodimer and heterodimer formation.\",\n      \"method\": \"Pull-down coupled with mass spectrometry, immunoblotting, siRNA knockdown of CEBPB/CEBPD, reporter assays for transcriptional activity\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased proteomics pull-down confirmed by immunoblot, siRNA functional validation; single lab\",\n      \"pmids\": [\"31676720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MDR (multidrug-resistant) cells lack C/EBP-β LIP due to constitutive ubiquitination leading to lysosomal and proteasomal degradation. Loss of LIP drives MDR by increasing P-glycoprotein (Pgp) expression and attenuating ER stress-triggered cell death through the CHOP-caspase-3 axis. LIP overexpression reversed the MDR phenotype in vitro and in vivo.\",\n      \"method\": \"Ubiquitination assays, proteasome/lysosome inhibitors, LIP overexpression in vitro and in vivo orthotopic tumor model, Pgp expression, CHOP-caspase-3 axis analysis\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination mechanism plus in vitro and in vivo rescue with isoform-specific overexpression; single lab\",\n      \"pmids\": [\"25766403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"C/EBPβ in myeloid cells is required for sepsis-induced generation of immunosuppressive MDSCs. Myeloid-restricted C/EBPβ-deficient mice do not generate MDSCs upon sepsis, do not develop immunosuppression, and survive sepsis at higher rates. C/EBPβ directs a switch from pro-inflammatory to repressor myeloid phenotype, but is not required for steady-state myelopoiesis.\",\n      \"method\": \"Myeloid cell-specific Cre-lox C/EBPβ deletion, cecal ligation/puncture sepsis model, MDSC flow cytometry, adoptive transfer, colony assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — myeloid-specific conditional KO with adoptive transfer and multiple functional readouts; rigorous genetic approach\",\n      \"pmids\": [\"28476751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NRF2 directly regulates CEBPB expression in NRF2-activated lung cancer cells; CEBPB cooperates with NRF2 to co-regulate genes involved in drug metabolism and detoxification, driving drug resistance. Comprehensive genomic analysis identified NRF2-CEBPB co-regulated genes enriched for drug resistance pathways.\",\n      \"method\": \"ChIP-seq, transcriptomic analysis of NRF2-activated lung cancer cells with CEBPB KO, drug resistance functional assays\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct regulation, KO functional assays; single lab\",\n      \"pmids\": [\"35137113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Autophagy (SQSTM1/p62-mediated) degrades CEBPB normally; autophagy deficiency leads to CEBPB accumulation, which in turn promotes transcription of SOCS1/3. Elevated SOCS1/3 inhibits JAK1-STAT6 pathway activation and M2 macrophage marker expression, demonstrating that autophagy controls macrophage M2 polarization through CEBPB degradation.\",\n      \"method\": \"Macrophage-specific Atg5 conditional KO mice, AD skin model, CEBPB ChIP for SOCS1/3 promoters, STAT6 phosphorylation assays, flow cytometry for M2 markers\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with multiple mechanistic readouts linking autophagy-CEBPB-SOCS-JAK1-STAT6; in vivo and in vitro validation\",\n      \"pmids\": [\"37963021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PGC1α binds CEBPB to promote CPT1A transcription and fatty acid oxidation (FAO), promoting radiation resistance in nasopharyngeal carcinoma. PGC1α/CEBPB/CPT1A constitutes a signaling axis for FAO activation.\",\n      \"method\": \"Co-immunoprecipitation of PGC1α and CEBPB, ChIP/reporter assays for CPT1A transcription, FAO assay, radiation resistance functional assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating direct binding, transcriptional reporter; single lab\",\n      \"pmids\": [\"30945396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PAK4 enhances CEBPB phosphorylation on Thr-235, and CEBPB binds the -1093 to -991 bp region of the CLDN4 promoter to transcriptionally upregulate CLDN4 expression, promoting breast cancer cell migration and invasion.\",\n      \"method\": \"ChIP confirming CEBPB binding to CLDN4 promoter, PAK4 phosphorylation assay, siRNA knockdown, migration/invasion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct promoter binding plus phosphorylation assay; single lab\",\n      \"pmids\": [\"30808546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CEBPB binds the TRIM2 promoter and acts as an upstream transcription factor for TRIM2. TRIM2 promotes p53 ubiquitination and degradation, thereby reducing p53 stability. Epinephrine signaling via β2-adrenergic receptor regulates CEBPB expression, placing CEBPB as an epinephrine-responsive upstream regulator of the TRIM2/p53 axis.\",\n      \"method\": \"ChIP assay for CEBPB binding to TRIM2 promoter, co-immunoprecipitation, p53 ubiquitination assay, β2-adrenergic receptor antagonist\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and co-IP; single lab, multiple methods\",\n      \"pmids\": [\"35672760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The C/EBPβ isoforms LAP and LIP differentially regulate cell cycle progression in regenerating liver. Adenoviral overexpression of LAP delays S-phase entry with decreased cyclin A/E, PCNA, and CDK2 activity, via decreased C/EBPα ratio and c-jun levels. LIP overexpression leads to stronger/earlier induction of cyclin A/E and more robust C/EBPα and c-jun induction, but does not alter S-phase entry timing.\",\n      \"method\": \"Adenoviral isoform overexpression, partial hepatectomy mouse model, CDK2 activity assay, Western blot for cyclins/PCNA\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific adenoviral overexpression in vivo with mechanistic cell cycle readouts; single lab\",\n      \"pmids\": [\"15368440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FUS-DDIT3 fusion oncogene in myxoid liposarcoma upregulates IL-6 expression in a C/EBPβ-dependent manner. siRNA knockdown of CEBPB transcripts abolishes FUS-DDIT3-induced IL-6 upregulation. ChIP revealed direct interaction between the IL-6 promoter and C/EBPβ protein in these cells.\",\n      \"method\": \"siRNA knockdown of CEBPB, ChIP assay, microarray, RT-PCR\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA functional epistasis plus ChIP for direct promoter binding; single lab\",\n      \"pmids\": [\"15688424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CEBPB binds the Pim-1 promoter and promotes Pim-1 transcription, which facilitates NLRP3 inflammasome activation and pyroptosis in glomerular podocytes in lupus nephritis. Knockdown of CEBPB suppresses NLRP3 inflammasome activation and IL-1β/IL-6 secretion; overexpression of Pim-1 reverses these effects.\",\n      \"method\": \"ChIP for CEBPB binding to Pim-1 promoter, Pim-1 overexpression rescue, shCEBPB lentivirus in MRL/lpr mice, NLRP3 inflammasome assays\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus in vivo KD and rescue with Pim-1 OE; single lab\",\n      \"pmids\": [\"36248187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CEBPB directly binds the SERPINA1 gene promoter and promotes SERPINA1 transcription; SERPINA1 in turn activates the STAT3 signaling pathway to promote CRC proliferation and migration. This CEBPB-SERPINA1-STAT3 axis drives colorectal cancer progression.\",\n      \"method\": \"ChIP assay, luciferase reporter gene assay, STAT3 pathway analysis, functional assays in CRC cells\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase reporter for direct regulatory relationship; single lab\",\n      \"pmids\": [\"38710698\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEBPB (C/EBP-β/NF-IL6) is a bZIP transcription factor that binds CCAAT/enhancer elements as homo- or heterodimers to directly activate or repress target genes involved in inflammation (IL-6, TNFα, G-CSF, iNOS), adipogenesis (PPARγ, C/EBPα), and survival (IGF-I, Bcl-2); its activity is post-translationally regulated by phosphorylation (via MAPK/RSK/GSK-3β/PKA/CREB cascades), isoform-specific translational control (producing the activating LAP and dominant-negative LIP isoforms from a single mRNA), ubiquitin-mediated proteasomal/lysosomal degradation (particularly of LIP), and selective association with distinct Mediator complexes (active CRSP70 vs. inactive CDK8 forms) driven by Ras-induced conformational changes; the full-length isoform additionally recruits the SWI/SNF chromatin remodeling complex through its unique N-terminal domain, and forms functional complexes with NF-κB p65 (blocking p65 phosphorylation), glucocorticoid receptor, PGC1α, CHOP, Elk-1, and HDAC1 to modulate transcription of genes controlling immunity, metabolism, differentiation, and stress responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CEBPB (C/EBPβ / NF-IL6) is a bZIP transcription factor that binds CCAAT/enhancer core elements as sequence-specific homo- or heterodimers to activate or repress genes governing inflammation, myeloid differentiation, adipogenesis, liver regeneration, and stress responses [#0, #2]. As a direct transcriptional regulator it activates pro-inflammatory and acute-phase targets including IL-6, TNFα, iNOS, and SerpinB2/PAI-2 [#0, #8, #23, #26], drives the adipogenic cascade by inducing PPARγ in synergy with glucocorticoid signaling [#2], and acts as a repressor of targets such as the albumin gene during liver regeneration and CD200R1 in activated microglia, where repression is mediated by recruitment of HDAC1 [#16, #21]. Beyond direct DNA binding, C/EBPβ functions through protein–protein partnerships: its full-length N-terminal domain recruits the SWI/SNF chromatin-remodeling complex to activate myeloid genes [#3], it cooperates with c-Myb through long-range DNA looping demonstrated structurally [#4], and it forms functional complexes with the glucocorticoid receptor, PGC1α, Elk-1, NF-κB p65, and CHOP to integrate hormonal, metabolic, and stress inputs [#20, #33, #25, #12, #10]. C/EBPβ activity is heavily controlled post-transcriptionally and post-translationally: it is converted from repressor to activator by MAPK/Ras-, RSK-, GSK-3β-, and PKA/CREB-driven phosphorylation that also dictates selective association with active versus inactive Mediator complexes and subnuclear relocalization [#5, #6, #7, #9, #13], and the LAP and LIP isoforms produced by isoform-specific translational control exert opposing effects on ER-stress-induced apoptosis, multidrug resistance, and cell-cycle progression [#10, #11, #29, #36]. Its abundance is further set by ubiquitin-, autophagy-, and translation-dependent turnover that tunes immune polarization and inflammatory output [#29, #32, #17]. In myeloid cells C/EBPβ is required for emergency generation of immunosuppressive MDSCs and for the switch from a pro-inflammatory to a repressor phenotype during sepsis and tumor-associated immune suppression [#30, #22]. Disease-linked roles include a δ-secretase-cleaved APP fragment that binds and hyperactivates CEBPB to amplify Alzheimer's disease pathology [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established the molecular identity of CEBPB as a sequence-specific bZIP activator, answering what kind of protein mediates IL-6-responsive enhancer activity.\",\n      \"evidence\": \"expression cloning, bacterial fusion-protein DNA binding, and reporter transactivation of the IL-6 promoter\",\n      \"pmids\": [\"2112087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo target spectrum defined\", \"Regulation of its activity not yet addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed CEBPB activity is controlled post-translationally, answering how IL-6 acutely boosts its function without new synthesis.\",\n      \"evidence\": \"identity comparison with IL-6DBP and DNA-binding assays after IL-6 stimulation\",\n      \"pmids\": [\"1380488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphorylation site not mapped\", \"Responsible kinase not identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defined CEBPB as a direct macrophage TNFα activator, distinguishing it functionally from C/EBPα.\",\n      \"evidence\": \"cotransfection reporter assays with a dominant-negative C/EBPβ and DNA binding\",\n      \"pmids\": [\"7929820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No endogenous knockout validation\", \"Site occupancy in vivo not shown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrated CEBPB can act as a direct repressor, broadening its role beyond activation during liver regeneration.\",\n      \"evidence\": \"in vitro transcription with recombinant LAP, EMSA on the albumin D site, and hepatectomy model\",\n      \"pmids\": [\"8703043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Corepressor machinery not identified\", \"Isoform-specific contribution to repression unresolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified the PKA/CREB pathway as an upstream regulator of CEBPB gene expression, linking cAMP signaling to its transcription.\",\n      \"evidence\": \"promoter deletion/mutagenesis, EMSA/supershift of CRE sites, and liver regeneration model\",\n      \"pmids\": [\"9199295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other inducible inputs to the promoter not enumerated\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Placed CEBPB upstream in the adipogenic cascade, answering what initiates PPARγ induction during preadipocyte commitment.\",\n      \"evidence\": \"tetracycline-regulated conditional expression in NIH-3T3 with PPARγ readouts and differentiation assays\",\n      \"pmids\": [\"7557387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect PPARγ promoter occupancy not resolved here\", \"Glucocorticoid synergy mechanism unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed that full-length CEBPB recruits a chromatin-remodeling machine, explaining isoform-specific activation in a chromatin context.\",\n      \"evidence\": \"interaction assays plus domain-swap chimera reconstituting SWI/SNF recruitment and mim-1 transcription\",\n      \"pmids\": [\"10619021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SWI/SNF subunit contacted not defined\", \"Generalizability beyond myeloid genes untested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed Ras-dependent partnership with Elk-1, connecting CEBPB to growth-factor-induced immediate-early transcription.\",\n      \"evidence\": \"GST pulldown, Ras-dependent co-IP, and SRE reporter assays with domain mapping\",\n      \"pmids\": [\"11151091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous SRE occupancy not shown\", \"Single-lab interaction\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided structural evidence for long-range cooperativity with c-Myb, explaining combinatorial promoter activation and v-Myb's defect.\",\n      \"evidence\": \"X-ray crystallography of ternary complexes, GST pulldown, AFM, and luciferase assays\",\n      \"pmids\": [\"11792321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of DNA looping not quantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linked CEBPB to hypoxia-induced iNOS transcription in vascular smooth muscle.\",\n      \"evidence\": \"iNOS promoter C/EBP-site mutation, EMSA, and hypoxia exposure\",\n      \"pmids\": [\"11834703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No loss-of-function validation\", \"Upstream hypoxia signaling to CEBPB unmapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established phosphorylation-driven subnuclear relocation, showing MAPK signaling repositions CEBPB to heterochromatin.\",\n      \"evidence\": \"immunofluorescence, phospho-site antibody, MEK inhibition, and satellite-DNA binding after GH stimulation\",\n      \"pmids\": [\"12821655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of pericentromeric targeting unclear\", \"Heterochromatin target genes unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined a Ras/MAPK conformational switch that toggles CEBPB between repressive and active Mediator complexes, providing a molecular mechanism for activity control.\",\n      \"evidence\": \"co-IP, RNAi of CRSP130/Sur2, activating mutations, and reporter assays\",\n      \"pmids\": [\"14759369\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the conformational change not solved\", \"Which target genes use each Mediator form not enumerated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified IGF-I as a direct survival target through which CEBPB enables oncogenic macrophage transformation.\",\n      \"evidence\": \"C/EBPβ-null cells with genetic rescue, IGF-I promoter reporter, and in vivo tumorigenicity\",\n      \"pmids\": [\"15060147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter occupancy by ChIP not shown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed LAP and LIP isoforms differentially set cell-cycle timing in regenerating liver, establishing isoform-specific functional divergence.\",\n      \"evidence\": \"adenoviral isoform overexpression in partial hepatectomy with cyclin/CDK2 readouts\",\n      \"pmids\": [\"15368440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect cyclin regulation unclear\", \"Single-lab in vivo overexpression\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established a neuronal regeneration role, showing CEBPB is required for injury-induced regeneration-associated gene transcription.\",\n      \"evidence\": \"C/EBPβ-null mice with Tα1 promoter reporter transgenes and facial nerve injury\",\n      \"pmids\": [\"15936952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream injury signaling to CEBPB not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed an anti-inflammatory braking function through complex formation with NF-κB p65, blocking p65 phosphorylation during TNF tolerance.\",\n      \"evidence\": \"C/EBPβ-null cells, reciprocal co-IP, phosphorylation and reporter assays\",\n      \"pmids\": [\"16785565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphatase or kinase blocked not identified\", \"Direct vs scaffolded inhibition unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed CEBPB is a differentiation-promoting target silenced translationally by BCR/ABL, linking its loss to leukemic block.\",\n      \"evidence\": \"BCR/ABL model, imatinib reinduction, CUGBP1 dependence, and DNA-binding-deficient mutant\",\n      \"pmids\": [\"16418324\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CUGBP1-mRNA contact not mapped here\", \"Differentiation target genes unspecified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Implicated CEBPB as the effector of a fusion oncogene-driven IL-6 program in liposarcoma.\",\n      \"evidence\": \"siRNA epistasis and ChIP of CEBPB at the IL-6 promoter\",\n      \"pmids\": [\"15688424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of FUS-DDIT3 activation of CEBPB unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined RSK phosphorylation of CEBPB as a fibrosis-driving survival switch in hepatic stellate cells.\",\n      \"evidence\": \"phospho-null C/EBPβ-Ala217 transgenic mice, CCl4 model, caspase-8 complex IP, and RSK-inhibitory peptide\",\n      \"pmids\": [\"18159255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How phosphorylation excludes CEBPB from death complex II mechanistically unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated GR–CEBPB cooperation drives corticosteroid-induced COX-2, integrating glucocorticoid signaling at a shared promoter.\",\n      \"evidence\": \"co-IP, ChIP, COX-2 promoter mutagenesis, and siRNA knockdown\",\n      \"pmids\": [\"18650268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the GR-CEBPB complex unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed the LIP isoform chaperones CHOP into the nucleus and amplifies ER-stress apoptosis, defining an isoform-specific pro-death function.\",\n      \"evidence\": \"C/EBPβ-null MEFs reconstituted with LIP, co-IP, fractionation, and apoptosis assays\",\n      \"pmids\": [\"20479126\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor used for LIP-CHOP transit not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established opposing LAP/LIP roles in tumor ER-stress survival, with LAP protecting and LIP sensitizing cells.\",\n      \"evidence\": \"inducible isoform overexpression with orthotopic tumors and UPR/cell-death markers\",\n      \"pmids\": [\"20209087\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct UPR target genes per isoform not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Captured an evolutionary rewiring of CEBPB phosphoregulation, showing how its GSK-3β/PKA response was reversed in placental mammals.\",\n      \"evidence\": \"ancestral protein resurrection with site-directed mutagenesis and functional phospho assays\",\n      \"pmids\": [\"22080951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological target genes affected by the rewiring not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified eIF4E-dependent translational control of CEBPB as the basis of IMiD anti-myeloma action and linked CEBPB to IRF4 regulation.\",\n      \"evidence\": \"stability/mRNA exclusion experiments, eIF4E manipulation, rescue, and patient sampling\",\n      \"pmids\": [\"21389327\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct IRF4 promoter occupancy not shown here\", \"Single-lab translational mechanism\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined an HDAC1-dependent repressive complex through which CEBPB silences CD200R1 in activated microglia.\",\n      \"evidence\": \"qChIP, co-IP of HDAC1-CEBPB, null primary microglia, and HDAC inhibitor reversal\",\n      \"pmids\": [\"22776069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other corepressors not excluded\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established CEBPB as a direct activator of both constitutive and LPS-induced SerpinB2 in macrophages.\",\n      \"evidence\": \"C/EBPβ-null MEFs/macrophages, EMSA, ChIP, and promoter mutagenesis\",\n      \"pmids\": [\"23472114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cooperating LPS-responsive factors not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed cytosine modifications tune CEBPB DNA binding, with 5hmC selectively inhibiting it in an isoform-specific manner.\",\n      \"evidence\": \"systematic EMSA across all CG modification states with CD validation\",\n      \"pmids\": [\"25779641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance at endogenous loci not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked ubiquitin-driven lysosomal/proteasomal LIP degradation to multidrug resistance through Pgp and the CHOP-caspase-3 axis.\",\n      \"evidence\": \"ubiquitination assays, degradation inhibitors, and LIP rescue in vitro and in vivo\",\n      \"pmids\": [\"25766403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase responsible for LIP ubiquitination unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established a myeloid-intrinsic requirement for CEBPB in sepsis-driven MDSC generation and immunosuppression.\",\n      \"evidence\": \"myeloid-specific conditional knockout, sepsis model, adoptive transfer, and MDSC profiling\",\n      \"pmids\": [\"28476751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CEBPB target genes mediating the repressor switch not enumerated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected tumor metabolism to immunosuppression through an AMPK-ULK1-autophagy axis controlling the LAP isoform and downstream G-CSF/GM-CSF.\",\n      \"evidence\": \"glycolysis inhibition, pathway manipulation, isoform-specific blots, and TNBC mouse models\",\n      \"pmids\": [\"29805099\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of autophagy-dependent isoform control unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified PRMT7 methylation of CEBPB as a brake on its adipogenic promoter occupancy.\",\n      \"evidence\": \"co-IP, methylation assay, ChIP at PPARγ2 promoter, and PRMT7-null MEFs\",\n      \"pmids\": [\"31371025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methylated residues not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed DN-ATF5 sequesters CEBPB by blocking dimer formation, and that CEBPB knockdown is selectively lethal to cancer cells.\",\n      \"evidence\": \"pull-down mass spectrometry, immunoblot, siRNA, and reporter assays\",\n      \"pmids\": [\"31676720\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cancer-specific dependency mechanism unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a PGC1α-CEBPB partnership driving CPT1A transcription and fatty-acid-oxidation-dependent radioresistance.\",\n      \"evidence\": \"co-IP, ChIP/reporter for CPT1A, FAO assay, and radiation-resistance readouts\",\n      \"pmids\": [\"30945396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs cooperative promoter binding not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked PAK4 phosphorylation of CEBPB Thr-235 to CLDN4 activation and breast cancer invasion.\",\n      \"evidence\": \"ChIP at the CLDN4 promoter, phosphorylation assay, siRNA, and migration/invasion assays\",\n      \"pmids\": [\"30808546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effect of phosphorylation on DNA binding vs activity unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a δ-secretase-truncated APP fragment as a direct CEBPB activator amplifying Alzheimer's pathology.\",\n      \"evidence\": \"co-IP, nuclear translocation and reporter assays, viral mouse model, and antibody clearance\",\n      \"pmids\": [\"33880508\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface on CEBPB not mapped\", \"Single-lab in vivo model\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified NRF2 as a direct regulator of CEBPB and a co-regulatory partner driving detoxification-linked drug resistance.\",\n      \"evidence\": \"ChIP-seq, transcriptomics with CEBPB knockout, and drug-resistance assays\",\n      \"pmids\": [\"35137113\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional separability of NRF2 vs CEBPB contributions limited\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed CEBPB upstream of the TRIM2/p53 axis as an epinephrine-responsive regulator destabilizing p53.\",\n      \"evidence\": \"ChIP at TRIM2 promoter, co-IP, p53 ubiquitination assay, and β2-adrenergic antagonist\",\n      \"pmids\": [\"35672760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect epinephrine-to-CEBPB link incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed CEBPB drives Pim-1-dependent NLRP3 inflammasome activation and podocyte pyroptosis in lupus nephritis.\",\n      \"evidence\": \"ChIP at Pim-1 promoter, in vivo shCEBPB, and Pim-1 overexpression rescue in MRL/lpr mice\",\n      \"pmids\": [\"36248187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream signal activating CEBPB in podocytes unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established that autophagy controls macrophage M2 polarization by degrading CEBPB, which otherwise drives SOCS1/3 to suppress JAK1-STAT6.\",\n      \"evidence\": \"macrophage-specific Atg5 conditional KO, CEBPB ChIP at SOCS1/3, and STAT6 phosphorylation readouts\",\n      \"pmids\": [\"37963021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"p62 recognition motif on CEBPB not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a CEBPB-SERPINA1-STAT3 axis promoting colorectal cancer progression.\",\n      \"evidence\": \"ChIP, luciferase reporter, and CRC functional assays\",\n      \"pmids\": [\"38710698\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect STAT3 activation unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many context-specific phosphorylation, methylation, and degradation inputs are integrated to select between CEBPB's activating and repressive output programs at the genomic level remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genome-wide map reconciling isoform, modification state, and target choice\", \"Structural basis of the repressor-to-activator conformational switch unsolved\", \"E3 ligases and the full degradation network controlling each isoform incompletely defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 8, 16, 23, 39]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 16, 19, 23, 26]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 10, 12, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 6, 10, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 16, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 12, 21, 23, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 15, 24]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 10, 26]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 13, 29, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MYB\", \"NFKB1/RELA\", \"CHOP/DDIT3\", \"ELK1\", \"NR3C1\", \"PPARGC1A\", \"HDAC1\", \"ATF5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}